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ABSTRACT OF THE DISSERTATION
ESTROGEN AND LITHIUM: FACILITATING FACTORS INVOLVED IN BRAIN
CELL SIGNALING PATHWAYS
by
James Jason Valdés
Florida International University, 2009
Miami, Florida
Professor Ophelia I. Weeks, Major Professor
Learning and memory in adult females decline during menopause and estrogen
replacement therapy is commonly prescribed during menopause. Post-menopausal
women tend to suffer from depression and are prescribed antidepressants – in addition to
hormone therapy. Estrogen replacement therapy is a topic that engenders debate since
several studies contradict its efficacy as a palliative therapy for cognitive decline and
neurodegenerative diseases. Signaling transduction pathways can alter brain cell activity,
survival, and morphology by facilitating transcription factor DNA binding and protein
production. The steroidal hormone estrogen and the anti-depressant drug lithium interact
through these signaling transduction pathways facilitating transcription factor
activation. The paucity of data on how combined hormones and antidepressants interact
in regulating gene expression led me to hypothesize that in primary mixed brain cell
cultures, combined 17β-estradiol (E2) and lithium chloride (LiCl) (E2/LiCl) will alter
genetic expression of markers involved in synaptic plasticity and neuroprotection. Results
from these studies indicated that a 48 h treatment of E2/LiCl reduced glutamate receptor
subunit genetic expression, but increased neurotrophic factor and estrogen receptor
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genetic expression. Combined treatment also failed to protect brain cell cultures from
glutamate excitotoxicity.
If lithium facilitates protein signaling pathways mediated by estrogen, can lithium
alone serve as a palliative treatment for post-menopause? This question led me to
hypothesize that in estrogen-deficient mice, lithium alone will increase episodic memory
(tested via object recognition), and enhance expression in the brain of factors involved in
anti-apoptosis, learning and memory. I used bilaterally ovariectomized (bOVX)
C57BL/6J mice treated with LiCl for one month. Results indicated that LiCl-treated
bOVX mice increased performance in object recognition compared with non-treated
bOVX. Increased performance in LiCl-treated bOVX mice coincided with augmented
genetic and protein expression in the brain. Understanding the molecular pathways of
estrogen will assist in identifying a palliative therapy for menopause-related dementia,
and lithium may serve this purpose by acting as a selective estrogen-mediated signaling
modulator.
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PREFACE

Prior to my acceptance into the Biological Sciences graduate program at Florida
International University I volunteered in the laboratory of my major advisor, Dr. Ophelia
Inez Weeks.

I was immediately assigned to statistically analyze and interpret a

behavioral study conducted by Dr. Claude-Henry Volmar, at the time a former Biology
master’s graduate. The behavioral study was to test the performance of lithium-treated
C57BL/6J male mice on an object recognition task (ORT), a task that measures episodic
memory.

An ORT involves mice recalling specific objects they were primed to

remember and their ability in recognizing novel objects. The hypothesis was that the
lithium-treated group will spend a greater amount of time with the novel object compared
with the control group. Statistical analysis of these experiments supported the hypothesis
that in these mice lithium increases episodic memory (e.g., novel object recognition).
Shortly after, an undergraduate at the time, Pablo Penaloza, analyzed lithium content
using blood samples from treated and control mice. Lithium-treated mice showed a
higher lithium-blood content than control.

Later, during my pre-doctoral studies, I

showed the lithium dosage used in the ORT study increases inhibition of a multifaceted
enzyme controlling transcription, cell death, mood-disorders, and neurodegenerative
diseases (a topic discussed throughout this dissertation).

Using the same blood samples from the ORT study, Pablo and I hypothesized that
since lithium and estrogen affect similar molecular pathways in the brain, there will be an
inverse correlation in estrogen versus lithium content in the blood – low estrogen content
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with high lithium content or vice versa.

Results from this analysis rejected our

hypothesis, since lithium raised estrogen levels in murine serum (unpublished data) – I
was still interested in the molecular relation lithium and estrogen share, though. These
molecular relations led to the overarching goal of my dissertation, that is: 1) to provide a
better understanding of how lithium and estrogen affect specific molecular markers in the
brain related to cell growth and survival (e.g. neuroprotection), learning and memory;
and, 2) if lithium alone can increase these molecular markers and increase episodic
memory in an estrogen-deficient model. I anticipate that a better understanding of such
mechanisms will offer avenues for developing palliative therapies for postmenopausalrelated cognitive decline and neurodegeneration.

To answer whether or not lithium influences estrogen-related pathways I used
primary brain cell cultures of fetal C57BL/6J mice (the highlights from those experiments
are noted in chapters one and two of my dissertation). I initially intended to harvest and
culture neurons for these experiments, unfortunately I cultured glia, the dominant brain
cell type. Glia not only provides support, nutrition, and maintenance of neurons but also
facilitates neuronal communication and growth. Notwithstanding, I continued to analyze
these samples and something fascinating happened: I obtained viable and interesting
results. I used quantitative polymerase chain reaction (qPCR) and cell viability assays to
generate and interpret data, revealing that lithium reduced estrogen-regulated gene
expression of glutamate receptors involved in learning and memory.

Furthermore,

lithium provided protection to glial cells against toxic levels of glutamate, and estrogen
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reduced this protective quality. A manuscript derived from these studies was submitted
and accepted to the journal Brain Research.

Using the genetic material from these same experiments I generated another
manuscript (chapter two). The second set of analyses addressed how combined treatment
of estrogen and lithium affect gene expression of factors involved in learning, memory,
and neuroprotection. Using qPCR interpreted data showed that combined treatment of
estrogen and lithium increases factors (i.e., transcription factors, proteins) involved in
learning

and

memory,

but

not

neuroprotection

among

glia-rich

cultures.

Chapter two is currently under review for publication in the journal Neuroscience Letters.

To test whether lithium alone can enhance learning and memory (and molecular
markers involved in these processes), I used estrogen-deficient mice (i.e. both ovaries
were removed). Estrogen-deficient mice were treated with lithium for one month. This
project utilized all the techniques I acquired up to this point to examine cognitive,
neuroendocrine and biochemical parameters. Results are specified in chapter three, and
indicate that lithium-treated estrogen-deficient mice, compared with non-treated
estrogen-deficient mice, show an increased performance in ORT (e.g. episodic memory).
The observed increase in performance coincides with an increase in specific molecular
makers in the brain involved in learning, memory and neuroprotection.

The final chapter of my dissertation (chapter four) is a literature review aided by
protein modeling techniques and in silico research. Chapter four examines how lithium
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and estrogen affect similar proteins involved in neuroprotection, learning and memory.
Extensive reports have examined neurological pathways associated with lithium and
estrogen individually, and my review serves as a bridge between lithium and estrogen by
recognizing possible links between them – in a molecular sense. I chose this as my last
chapter to encapsulate a theoretical mechanism of my dissertation and to provide a
platform for future studies incorporating my experimental parameters.

Ultimately, my dissertation investigates how estrogen and lithium affect
molecular markers in the brain involved in learning, memory and neuroprotection. Postmenopausal women suffer from a lack of circulating estrogen and are often prescribed
hormone replacement therapy; but some also suffer from depression and are often
prescribed antidepressants. Understanding the interactions of estrogen and lithium will
provide a better treatment regime for post-menopausal women.

As I show in this

dissertation, lithium alone increases episodic memory in estrogen-deficient mice. This
interpretation may market lithium as a palliative treatment for post-menopausal-related
cognitive decline – although lithium is traditionally used for treating psychiatric
disorders.
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CHAPTER I
Estradiol and Lithium Chloride Specifically Alter Glutamate Receptor Subunit Genetic
Expression and Excitotoxicity in Primary Cultures

Abstract
Glutamate facilitates calcium influx via N-methyl-D-aspartate (NMDA) receptor, and
excess calcium influx increases excitotoxicity – a pathological characteristic of
neurological diseases. Both 17β-estradiol (E2) and lithium influence NMDA receptor
expression/signaling and excitotoxicity. This led me to hypothesize that combined E2
and lithium will alter NMDA receptor expression and excitotoxicity.

I tested this

hypothesis using primary cell cultures from the cortex and hippocampus of C57BL/6J
fetal mice pretreated with E2, lithium chloride (LiCl) and combined E2/LiCl for 12, 24 or
48 h.

I examined cultures for brain cell type and changes in cell type caused by

experimental procedures using glia and neuron gene specific primers. These cultures
expressed increased glial fibrillary acidic protein (GFAP) mRNA with low
neurofilament-heavy chain (NF-H) mRNA expression. Subsequent analysis of cortical
cell cultures indicated that combined E2/LiCl decreased NR1 mRNA expression after a
12 and 48 h treatment period. Combined E2/LiCl also reduced NR1 mRNA expression
in hippocampal cultures but only after a 48 h treatment period. Hippocampal LiCltreated cultures also reduced NR1 mRNA expression after a 24 and 48 h treatment. I
next examined the response of 48 h pretreated cultures to a toxic level of glutamate.
Excitotoxicity was measured using fluorescein diacetate/propidium iodide (FDA/PI) cell
viability assay. Results from FDA/PI assay revealed that LiCl pretreatment increased
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viability for cortical cultures while E2 and combined E2/LiCl reduced viability. All
pretreatments for hippocampal cultures failed to increase viability. My results showed
combined E2/LiCl reduced NR1 mRNA and prevented protection against glutamate
excitotoxicity in glial primary cultures.

1.1 Introduction
Estrogen-mediated neurobiological processes are involved in a myriad of signal
transduction pathways. These pathways result in enhancing synaptic plasticity [31],
reducing apoptotic activity in cortical neurons [21], regulating neurotrophic factors [55],
and facilitating transcription factor activation – e.g. cAMP response element binding
protein (CREB) [36]. Estrogen is considered an activating agent in N-methyl-D-aspartate
(NMDA) receptor signaling pathways [24], and NMDA receptor forms a heteromeric
glutamate receptor composed of the subunits NR1, NR2A-D and NR3 [56]. Expression
of NR1, NMDA receptor critical subunit, is increased in estrogen-induced primary
hippocampal neuronal cell cultures [24].

Similar cultures show increased levels of

intracellular calcium, mediated by the activation of L-type calcium channels, which in
turn

promote

signaling

pathways

that

activate/phosphorylate

CREB.

This

activation/phosphorylation promotes anti-apoptotic events [59]. Estrogen also facilitates
a transient activation of glycogen synthase kinase-3beta (GSK-3β). Estrogen receptorα (ER-α), when bound by its ligand estrogen, forms a complex with GSK-3β that
facilitates regulation of beta-catenin transcriptional properties [7]. Response element
binding of ER-α relies on GSK-3β phosphorylation and this phosphorylation is inhibited
in the presence of lithium [37]. Contrary to this synergistic relation of ER-α and GSK-
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3β, other studies show estrogen facilitating an inhibition of GSK-3β. This inhibition is
dependent on kinase phosphorylation mediated by estrogen receptor signaling [16].
Interestingly, GSK-3β activity influences NMDA receptor signaling and NMDA receptor
subunit expression. Electrophysiological studies using mouse hippocampal slices report
that GSK-3β activity is increased during long-term depression. This increase reduces
during NMDA receptor-mediated long-term potentiation [46].

Selective GSK-

3β inhibitors also reduce NMDA receptor synaptic currents and receptor internalization
in cortical cell cultures. Cultures expressing a knockdown of GSK-3β exhibit similar
effects [8].

Over a decade has passed since Klein and Melton (1996) demonstrated lithium
specifically inhibiting GSK-3β [28]. This inhibition is associated with reducing apoptotic
activity [22], increasing neurotrophic factors [2], and facilitating CREB DNA binding
[17, 45]. Though the mechanism remains elusive, lithium indirectly inhibits GSK-3β by
activating protein kinases that phosphorylate GSK-3β at serine 9 and/or by inactivating
phosphatases that remove this phosphate group [26]. Direct inhibition involves lithium
acting as a competitive inhibitor of magnesium; magnesium being a cofactor for ATP in
GSK-3β activation [52]. Aside from lithium’s inhibitory action on GSK-3β, there is an
indirect effect on NMDA receptor signaling pathway.

This involves reducing

phosphorylation/activation of Src tyrosine kinases, potentially affecting any NMDA
receptor-regulated excitotoxicity. Phosphorylation of NR2 subunits of NMDA receptor
by Src tyrosine kinases is essential for the receptor’s signal transduction activity [see 18].
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Using lithium-treated rat cerebral cortex neurons, Hashimoto et al. (2003) demonstrated
that phosphorylated levels of Src tyrosine kinase is decreased in a time-dependent
fashion. Lithium, however, does not seem to influence NMDA receptor subunit protein
expression [44].

Expression of NR1 increases in estrogen-treated primary hippocampal neuronal
cultures [24], and similar cultures also show increase intracellular calcium levels [59].
But lithium reduces NMDA receptor-mediated glutamate excitotoxicity by reducing
calcium influx [10].

While NMDA receptor is classically regarded as a neuronal

receptor, these receptors are also found on cortical astrocytes [12]. Astrocytes process
the neurotransmitter glutamate to reduce excitotoxic insults to neurons; however,
astrocytes themselves are not as susceptible to excitotoxicity as are neurons [see 35]. In
astrocyte cultures from the rat olfactory bulb, estrogen receptor agonists reduce secretion
of specific markers responsible for inflammatory responses (e.g. interleukin-1, tumor
necrosis factor-α, and matrix metallopeptidase 9) [32]. As well, astrocytes produce and
secrete estrogen, influencing communication among neurons.

When cultures of rat

cortical neurons are exposed to media from cultured astrocytes, neuronal synaptic
formation and impulse transmission increase, due to the presence of estrogen in the
astrocytic media [23].

Glutamate excitotoxicity mediated by NMDA receptor is a pathological element
in many neurodegenerative diseases and analysis of how combined estrogen and lithium
influence NMDA receptor regulation and its mediated pathways are wanting. Since
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estrogen and lithium are involved in regulating NMDA receptor activation/function I
hypothesized that combined estrogen (specifically 17β-estradiol; E2) and lithium chloride
(LiCl) (E2/LiCl) will alter mRNA expression of NMDA receptor subunit NR1 in primary
cultures harvested from mouse cortex and hippocampus. The premise of this hypothesis
is that estrogen receptor-α facilitates NMDA receptor subunit expression and studies
have shown that estrogen receptor-α response element binding is attenuated in the
presence of lithium [37]. My results indicate that combined E2/LiCl treatment reduce
NR1 mRNA expression of primary cultures expressing high levels of glial-specific
mRNA. I chose this course of study since glia express NR1 [12], and NR1 is the critical
subunit of a functional NMDA receptor. These results led me to further hypothesize that
amongst these primary glial cultures combined E2/LiCl will alter protective features (cell
viability) against glutamate insult. I tested this hypothesis using a cell viability assay
with 48 h pre-treated primary cultures exposed to high levels of glutamate.

High

glutamate concentration was necessary since glia are extremely tolerant to excitotoxicity
[see 35].

My results indicated that while LiCl reduced NR1 mRNA in E2-treated

cultures, E2 compromised cell viability in LiCl treated cultures. In many instances postmenopausal women undergoing hormone therapy are also prescribed lithium (for
depression) and the interaction of these two agents are poorly understood. This is the
first study to note the influence of combined E2/LiCl on expression of receptors involved
in learning, memory and mediating excitotoxic effects.
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1.2 Experimental Procedures
1.2.1 Primary Mixed Brain Cell Cultures
I used C57BL/6J mice bred at Florida International University. Animals
were kept in an environment of 22°C temperature, 60% humidity, within
polycarbonate transparent cages (26.7 cm x 20.6 cm x 14 cm) on a 12 h day-night
cycle with free access to water and food. All experiments were approved by the
Institutional Animal Care and Use Committee (Approval Number: 08-017).
Primary cultures were harvested from E18.5 C57BL/6J mice. Pregnant mice (n =
5) were euthanized by cervical dislocation, E18.5 fetal mice were then removed
via caesarian section, decapitated, brains removed, and placed in ice-cold Earle’s
balanced salt solution (EBSS; Hyclone, Utah). The cortex and hippocampus from
each hemisphere were isolated under a dissecting microscope and washed with
fresh ice-cold EBSS. Tissue was mechanically triturated, passed through a 70µm
pore filter, and cells were counted using a hemocytometer. Disassociated cells
were randomly plated (6 x 106 for cortical cultures and 3 x 106 for hippocampal
cultures) on poly-D-lysine (100µg/mL; Sigma-Aldrich, Missouri) coated 12-well
plates containing B27/Neurobasal medium (Invitrogen, California) with 0.5mM
L-glutamine and 4µg/mL gentamicin. Additional 12-well plates, with poly-Dlysine (100µg/mL) coated coverslips were set aside for viability assessment.
Cells were maintained in a humidified, 5% CO2 atmosphere incubator with a set
temperature of 37°C. After 4 days in culture, the media was removed entirely and
replaced with fresh media; half of the media was changed every 4 days, thereafter,
until E2 and/or LiCl treatment.
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1.2.2 Chemicals and Treatments
After twelve days in culture, the media was removed entirely and replaced
with media treated with 10mM LiCl (Sigma-Aldrich, Missouri), 0.04µM E2
(Sigma-Aldrich, Missouri), or combined E2 and LiCl. Duration of treatment for
each group was 12, 24, and 48 h. Additionally, cell viability was measured using
48 h pretreated cells exposed to 100µM glutamatic acid (Sigma-Aldrich,
Missouri) for 1 h at 37°C.

1.3 Experimental Techniques
1.3.1 Total RNA Isolation and cDNA Synthesis
Total RNA was extracted from cultured cells after treatment with TRIzol reagent
(GIBCO, California), according to manufacturer’s protocol. Briefly, cultures were rinsed
with ice-cold DPBS, TRIzol Reagent (600µL-1mL) was added directly into each well,
and cultures were homogenized. Homogenized cells were then transferred to a fresh
tube, and incubated at room temperature. Chloroform was added and centrifuged at
10, 000 rpm at 4°C. Total RNA (aqueous phase) was transferred to a sterile tube and
allowed to precipitate with isopropanol and glycogen overnight at -20°C. The RNA was
pelleted via centrifugation at 10, 000 rpm at 4°C, supernatant was decanted and RNA
pellet was washed twice with 75 % ethanol. Pellets were then air dried and resuspended
with DEPC-treated water. Contaminants of DNA were removed with the RQ1 DNase kit
(Promega, Wisconsin). Samples were stored at -80°C until they were further processed.
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Reverse transcription (RT) was performed using SUPERSCRIPTTM II RNase Hfree reverse transcriptase (Invitrogen, California), according to the manufacturer's
protocol. Briefly, 500ng of total RNA was reverse transcribed with 0.05µg/µl of Oligo
(dT)12-18 at 65°C for 5 minutes. First strand cDNA was synthesized with 5mM MgCl2,
10mM DTT, and 1.5 units Superscript II and incubated at 42°C for 50 minutes; reaction
was terminated at 70°C for 15 minutes. The RNase H (Invitrogen, California) was
incubated at 37°C for 20 minutes once the first strand was synthesized to remove any
remaining RNA.

1.3.2 Cell-Typing Cultures using RT-PCR and Gel Electrophoresis
First strand cDNA was amplified via real time polymerase chain reaction (PCR)
using NF-H (forward primer 5'-AGCCCAAGGACTCTACAGCA-3'; reverse primer, 5'CTTTGGCTTTTCCGTCTCTG-3')

and

GFAP

(forward

primer

5'-

AGAAAACCGCATCACCATTC-3'; reverse primer, 5'-TCACATCACCACGTCCTTGT
-3') and GoTaq® (Promega, Wisconsin).

Cycling parameters for an Eppendorf

Mastercycler Gradient were set for: denaturing at 95°C for 30 seconds, annealing
temperature of 57°C or 64°C for 30 seconds, and extension at 72°C for 30 seconds, for a
total of 30 cycles, followed by a final extension at 72°C for 10 minutes.

After

amplification, samples were subjected to gel electrophoresis using a 1.5% agarose gel
stained with ethidium bromide and photographed using Digital Imaging Filter/Ethidium
Bromide (Fotodyne, Wisconsin) under UV light. Resulting band intensities were based
on two replicates and analyzed using ImageJ software band analyzer [49]. Measurements
are represented in arbitrary units and obtained by dividing the pixel integrated density
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(integrated density = area x mean pixel value) from each band of NF-H or GFAP by the
absolute intensity of the standard – HPRT.

1.3.3 Quantitative Real Time RT-PCR
First strand cDNA was amplified via real time PCR using SYBR Green PCR
master mix (ABgene, New York), 200-300nM of forward and reverse primers using
iCycler (BioRad, California) with IQ iCycler software (version 3.1). Cycling parameters
were set at: 95°C 15s, 57°C 30s, and extension at 72°C for 30s, for a total of 40 cycles,
followed by a final extension at 72°C for 10 minutes. The specific primer pairs were:
NMDA receptor subunit NR1: forward primer, 5'-ACTCCCAACGACCACTTCAC-3;
reverse primer, 5'-GTAGACGCGCATCATCTCAA-3'; HPRT: forward primer, 5'GGAGCGGTAGCACCTCCT-3'; reverse primer, 5'-AATCCAGCAGGTCAGCAAAG3'. All samples were compared with a standard curve comprised of pDNA of HPRT and
NR1 with pDNA generated using TOPO TA Cloning® Kit (Invitrogen, California).
Readings were normalized by dividing mRNA starting quantity (SQ) of NR1 by the
house-keeping gene HPRT mRNA SQ; output is in femtograms (fg) of mRNA.

1.3.4 Cell Viability – Fluorescein Diacetate/Propidium Iodide Assay
Cortical and hippocampal cells were cultured on 18mm coverslips cultures and
pretreated for 48 h with E2, LiCl, and combined E2 and LiCl (as described previously).
Excitotoxicity was induced for 1 h with 100µM glutamate. Cell viability of cultures was
determined after glutamate excitotoxicity through the use of a fluorescein diacetatepropidium iodide labeling technique [25]. Briefly, cells were quickly rinsed with ice-cold
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Dulbecco’s Phosphate Buffer Saline (DPBS). Approximately 150µL cocktail of 2µg/mL
of fluorescein diacetate and 0.6µg/mL propidium iodide was added directly to the
coverslip with adhered cells and incubated at room temperature. Each 18mm coverslip
was placed against a grid and images were captured from five subdivisions on the grid
(upper right, upper left, lower right, lower left, and center). Images were captured from 3
replicates per subdivision – a total of 15 images per coverslip – with a Leica inverted
epifluorescent microscope with a QImaging Micropublisher 3.3 cooled RTV camera and
processed using ImageJ Cell Counter. For a comparison prior to any experimental
procedure I assayed a separate culture designated as Initial Viability.

1.3.5 Statistical Analysis
Data are presented as the mean ± S.E.M and statistical significance was
determined by analysis of variance (ANOVA) followed by Fisher’s least significant
difference (LSD) post-hoc testing. Significant differences have a p-value < .05. All
results were obtained from two separate experimental procedures – except for glutamate
excitotoxicity which was based on triplicates from one experiment (see section 4.3.4 in
Experimental Procedures). Each level for all factors was randomly determined.

1.4 Results
1.4.1 Brain cell typing of primary cultures indicated predominance for glia
Figures 1A-D depicts densitometric data (gene/HPRT) obtained after RT-PCR
and gel electrophoresis (gels represented above the graph). I chose to analyze brain cell
type using gene specific primers for neurons and glia. The use of specific primers
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allowed me to monitor brain cell type and to monitor how my experimental parameters
affected neuronal and glial gene expression.

I used gene specific primers for glial

fibrillary acidic protein (GFAP) and neurofilament heavy chain (NF-H), markers readily
used for identifying glial and neuronal populations, respectively.

Using ANOVA,

densitometric data indicated a significant difference in gene expression (p < .001). These
primary cell cultures expressed high levels of GFAP mRNA (figures 1A & C) but with
consistently low levels of NF-H mRNA (figures 1B & D).

My experimental parameters altered genes expression for cortical but not
hippocampal cultures.

Expression of GFAP mRNA gradually increased for cortical

cultures during the 12, 24, and 48 h period (figure 1A), while hippocampal cultures
maintained consistency in GFAP expression (figure 1B). Expression of NF-H, however,
was more abundant in hippocampal cultures (figure 1D) compared with cortical cultures
(figure 1B) and this was consistent throughout treatment periods. Treatment did not
affect GFAP or NF-H mRNA expression within each respective culture type (cortical or
hippocampal). Overall, densitometric data demonstrated that both culture types expressed
high levels of GFAP mRNA compared with NF-H indicating these cultures were
predominantly glial.
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Figures 1A-D: ImageJ densitometric data obtained from RT-PCR and electrophoresis.
Analysis was performed via electrophoresis of RT-PCR samples using a 1.5% agarose
gel, gel images captured, and analyzed using ImageJ. Low visibilities of bands are due to
low mRNA expression. Total RNA from and reverse transcribed E18.5 cortical (A & B)
and hippocampal (C & D) primary cell cultures were isolated from Control (no
treatment), 0.04µM E2, 10mM LiCl, and combined E2/LiCl treated for 12, 24, and 48 h.
cDNA was then amplified via PCR using gene specific primers for GFAP (A & C) or
NF-H (B & D). Measurements were based on relative pixel intensity (integrated intensity
of GFAP/HPRT or NF-H/HPRT) and expressed in arbitrary units. Gels are represented
for each gene and treatment period (represented above the graph).

1.4.2 Combined E2/LiCl treatment reduced NR1 mRNA expression
Next, I examined the effect of my experimental design on NR1 mRNA
expression. The critical subunit of the NMDA receptor is NR1 and no studies have
investigated how combined E2/LiCl affects NR1 expression in glial cultures.
Additionally, in analyzing NR1 gene expression I can postulate transcriptional activity
caused by my treatment parameters. Interpretation of ANOVA on real time RT-PCR data
showed significant differences (p < .001) in NR1 mRNA expression related to treatment.
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Both treated culture types (cortical and hippocampal) slightly differed in overall NR1
mRNA expression (figures 2A & B), but this difference was not significant (p > .057).
No significant changes were noted across treatment periods (p > .2) – e.g., in a timedependent fashion; although, NR1 expression significantly changed among treated
culture types at specific time periods (p < .001).
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Figures 2A-B: Quantitative RT-PCR of NR1 mRNA expression. E18.5 cortical (A) and
hippocampal (B) primary cell cultures treated for 12, 24, and 48 h with 0.04µM E2,
10mM LiCl, combined E2/LiCl, or Control (no treatment). After temporal treatment total
RNA was isolated and reverse transcribed. The figure denotes NR1 mRNA expression in
femtograms (y-axis) and treatment duration (x-axis). *, p-value < .05 compared with
control; #, p-value < .05 compared with E2; †, p-value < .001 compared with 12 h
treatment.

No significant effects were detected for Control or E2 treatment on NR1 mRNA
expression across treatment periods and culture type (figure 2A & B). Expression of
NR1 was influenced by LiCl, but this alteration was dependent on culture type. In
cortical cultures (figure 2A), LiCl seemed to reduce NR1 gradually and specifically after
a 48 h treatment period, but according to Fisher’s LSD this decrease proved to be nonsignificant (p > .1).

For hippocampal cultures, Fisher’s LSD indicated that LiCl

significantly decreased (p < 0.05) NR1 mRNA expression after a 24 and 48 h treatment
period when compared with the 12 h treatment period (figure 2B).

Also, LiCl

significantly reduced (p < 0.05) NR1 expression in hippocampal cultures after a 48 h
treatment period when compared with Control and E2 treatments (figure 2B). Although
all treatments appeared to reduce hippocampal culture NR1 gene expression after 12 h
when compared with Control (figure 2B), Fisher’s LSD indicated this change was nonsignificant (p > .05).
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Combined E2/LiCl treatment significantly decreased (p < .05) NR1 mRNA
expression in both cortical and hippocampal cultures (figure 2A & B). Fisher’s LSD
showed that combined E2/LiCl treatment significantly reduced cortical NR1 mRNA
expression after 12 h when compared with E2 treated cultures (figure 2A).

This

significant decrease reoccurred after cortical cultures were treated with combined
E2/LiCl for 48 h. The 48 h decrease was noted when combined E2/LiCl was compared
with E2 and Control (figure 2A). Cortical cultures treated after 24 h did not alter NR1
mRNA expression. In hippocampal cultures, combined E2/LiCl treatment significantly
reduced NR1 expression. Combined E2/LiCl treatment when compared with Control and
E2 significantly reduced (p < 0.05) NR1 expression after a 48 h treatment period (figure
2B). No significant differences were noted for combined E2/LiCl treated hippocampal
cultures after a 12 and 24 h treatment, though.

These results demonstrated that combined E2/LiCl treatment decreased NR1 gene
expression for both culture types, specifically after a 48 h treatment period. Cortical
cultures showed significantly decreased NR1 gene expression after 12 and 48 h treatment
periods and hippocampal cultures showed significantly decreased expression only after a
48 h treatment period. Additionally, NR1 gene expression in LiCl-treated hippocampal
cultures decreased after a 24 and 48 h when compared with 12 h treatment period.
Cultures treated with E2 did not affect NR1 mRNA expression across all experimental
parameters.
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1.4.3 Combined E2/LiCl and E2 failed to reduce excitotoxicity
Glia are extremely tolerant to excitotoxicity [see 35] and since my primary
cultures express high glial mRNA (see figures 1A-D) a high dosage of glutamate
(100µM) was necessary. In my experiment, primary cell cultures were pretreated for 48
h, subjected to excitotoxicity with glutamate, and assessed for cell viability using
fluorescein diacetate/propidium iodide assay (FDA/PI). Figure 3A displays captured
images of primary cultures after experimental procedures. Live cells were labeled green
(FDA) and dead cells were labeled red (PI).

These primary cultures maintained a

tolerance for glutamate toxicity without treatment (Control) when compared with Initial
Viability (i.e., assayed prior to any experimental procedure).

Additionally, Control

cortical cultures compared with Initial Viability showed an increase in FDA labeling
(figure 3A). Increased Control FDA labeling did not occur for hippocampal cultures,
though (figure 3A). Pretreatment with E2 and combined E2/LiCl decreased viability for
both cortical or hippocampal cultures, as indicated by the intense PI labeling; however,
LiCl-treated cortical cultures showed increased cell viability which did not occur for
hippocampal (figure 3A). These images were then processed using ImageJ cell counter
[49] and data generated were statistically analyzed using ANOVA.
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Figure 3A-3B: Mean viability for glutamate excitotoxicity from 48 h treated cortical
(grey bars) and hippocampal (black bars) primary cell cultures. A pre-treatment
measurement (Initial viability) was assayed to note any changes caused by the treatment
and glutamate excitotoxicity. Images were captured (green labeling, fluorescein diacetate
(FDA; live cells) and red labeling, propidium iodide (PI; dead cells)) and viability
(FDA/(FDA+PI)) was assessed using ImageJ Cell Counter for both cortical and
hippocampal primary cultures. *, significantly reduced cell viability compared with
Initial Viability and Control (p-value < .05); #, significantly increased cell viability when
compared with Initial Viability (p-value < .05); †, significantly increased cell viability
when compared with other treatments (p-value < .05).

Viability was not reduced for Control cortical and hippocampal cultures when
compared with Initial Viability after glutamate excitotoxicity (figure 3B); specifically in
Control cortical cultures where viability significantly increased (p < .05) (figure 3B).
Figure 3B indicated cortical cultures pretreated with E2 and combined E2/LiCl
significantly failed to rescue cells from glutamate excitotoxicity when compared with
Control and Initial Viability. Cortical cultures treated with LiCl, however, exhibited
increased cell viability when compared with other treatment types and Initial Viability
(figure 3B). Figure 3B also depicts that all pretreated hippocampal cultures failed to
rescue cells from glutamate excitotoxicity when compared with Control and Initial
Viability. Hippocampal cultures also did not display increased cell viability because of
glutamate (e.g. Control) as did cortical cultures.

24

1.5 Discussion
Several cell signaling transduction pathways are affected by E2 and LiCl, but few
studies concentrate on any neurobiological effects the two combined may present.
Additionally, investigations are wanting on how combined E2 and LiCl affect glia. In the
mammalian brain glia are ten times more numerous than neurons and such would be
expected to play a role in the progression of neurodegenerative diseases [see 57]. In this
study, densitometric results showed high levels of GFAP mRNA expression among
cortical and hippocampal cultures (see figures 1A & C) compared with NF-H (see figures
1B & D), suggesting a predominance of glia. I chose to use GFAP and NF-H since these
are standard markers in identifying brain cell type (glia or neuron, respectively). Cultures
used in this study were harvested at a late embryonic age (E18.5) when most neurons
have differentiated. As expected, neurons harvested at E18.5 would have a greater
propensity for cell death during mechanical trituration, hence the low NF-H expression
(see figures 1B & D). Primarily, B27/Neurobasal medium is used for culturing cortical
and hippocampal neurons and this medium generates a 90% neuronal population
compared with a 10% glial population as described by immunocytochemistry [3]. Glia
population percentage coincides with my FDA/PI assay of Initial Viability (e.g. viability
assayed prior to any experimental procedures; see figures 3B) for both cortical and
hippocampal cultures since B27/Neurobasal media maintained a neuronal population
while suppressing glia proliferation. This allowed me to maintain cultures that sustained
neurons (see figures 1B & D), suppressed glia proliferation, but still with a predominance
of glial cells (see figures 1A & C). Densitometric data (figures 1A-D) indicated that
cortical cultures increased and were higher in GFAP mRNA expression across treatment
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periods (see figure 1A) compared with hippocampal cultures (see figure 1C). Glia are
constantly proliferating and this gradual increase and higher GFAP expression in cortical
cultures could be explained since cortical cultures were plated at a higher density than
hippocampal cultures (see Experimental Procedures). Hippocampal cultures expressed
higher levels of NF-H mRNA (see figure 1D) compared with cortical cultures (see figure
1B), but still, with higher GFAP levels than NF-H (see figure 1C & D). Rocha et al.
(1994) indicated that GFAP protein expression increased in the caudate nucleus and
hippocampus of 4 week lithium-treated rats [50] and though I noted GFAP mRNA
increased in cortical cultures (specifically at 24 and 48 h; see figure 1A) this was not
apparent in hippocampal cultures. This may be a result of my treatment being an acute
(up to 48 h) rather than a chronic one (4 weeks).

Glia, like neurons, are also known to express functional NMDA receptor and nonNMDA receptor [12, 30]. Glia NMDA receptor expression increases susceptibility to
excitotoxicity and facilitates glutamate transport [see 35].

Glial susceptibility to

excitotoxicity, however, is less severe than neuronal. This is of specific interest since
NMDA receptor subunit expression and excitotoxicity of glia are rarely studied. The
critical subunit of NMDA receptor is NR1 and without it there is no functional receptor.
In studying glial NR1 gene expression within my experimental parameters I can postulate
transcriptional activities affected (e.g., estrogen receptor-α/GSK-3β-mediated pathways
or CREB). Among both culture types, hippocampal cultures expressed higher levels of
NR1 mRNA (see figure 2B) compared with cortical cultures; this difference is worth
discussing even with p-value = .058 (see figure 2A). Both cultures expressed high levels
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of GFAP but hippocampal cultures also expressed higher levels of NF-H (see figure 1D)
compared with cortical cultures (see figure 1B). The higher levels of NR1 mRNA
expression in hippocampal cultures is that glia express functional NMDA receptor at a
lower level than neurons [see 11]. Additionally, autoradiography using NMDA receptorspecific ligands depict higher density of NMDA receptor in hippocampal regions than
cortical [41]. My study showed no effect of E2 treatment on NR1 mRNA expression for
both culture types (see figures 2A & B). My E2 results on NR1 mRNA contradicts Jelks
et al. (2007) findings where E2 treatment increased NR1 in neuronal cultures [24], but
my cultures did express higher levels of GFAP mRNA (see figures 1A & C). Few
studies investigate how E2 (or lithium) influence glia but I suggest my glia cultures
reached a saturation point since glia also produce estrogen – as noted in astrocytic culture
media [23]. The E2-estrogen receptor complex have a Kd of 150pM [53], therefore,
doses of .04µM E2 may have been negligible in altering NR1 mRNA expression.
Expression of NR1 mRNA did not change in LiCl-treated cortical cultures (see figures
2A) across treatment periods which coincides with Hashimoto et al. (2002) who showed
that lithium does not influence NR1 protein expression in neuronal cultures [19].
Treatment of LiCl, however, did reduce NR1 mRNA expression in hippocampal cultures
after a 24 and 48 h treatment period compared with 12 h LiCl-treatment (see figures 2B).
Lithium diffuses into a cell via sodium channel but also through glutamate receptors [27].
I clearly show that hippocampal cultures express higher levels of NR1 mRNA (see figure
2B) than cortical cultures (see figure 2A) and this may be indicative of functionally
expressed NMDA receptor. Hippocampal NR1 mRNA down-regulation by LiCl may be
caused by the influx rate of LiCl. This rate will change NR1 expression since estrogen
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receptor-α is involved in facilitating NMDA receptor subunit expression [see 58] that is
mediated by GSK-3β [see 37]; and lithium is known as a selective inhibitor of GSK-3β
[26].

The purpose of this study was to note the combined affect of E2 and LiCl on NR1
mRNA expression and excitotoxicity.

After a 12 h treatment, NR1 expression for

cortical cultures was not altered with individual treatment of E2 or LiCl; however, when
LiCl was combined with E2, NR1 expression decreased after 12 h (see figure 2A).
Hippocampal cultures did not display this reduction at 12 h, though (see figure 2B).
Studies show that in rat cerebral cortex hormone and dopamine-stimulated adenyl cyclase
activity is hindered by lithium [43]. Adenyl cyclase produces cAMP, a main constituent
in CREB signaling pathway. Activated CREB is highly involved in facilitating NMDA
receptor subunit expression [48] and reduced NR1 at 12 h may be caused by LiCl
inhibiting cortical adenyl cyclase activity triggered by E2. Combined E2/LiCl did not
alter NR1 expression in cortical and hippocampal cultures after 24 h treatment (see figure
2A & B). Therefore, the 12 h decrease in cortical NR1 mRNA may be caused by the fast
action of extracellular LiCl concentration inhibiting adenyl cyclase activity [6] as
opposed to intracellular concentration since reduced cortical NR1 mRNA reoccurred at
48 h treatment period for both culture types. The decrease in NR1 after 48 h was
significant compared with Control and E2 treated cortical and hippocampal cultures (see
figures 2A & B). Reduced NR1 at 48 h with combined E2/LiCl occurred for both
cultures indicating a similar pathway involved, possibly through the intracellular estrogen
receptor-α/GSK-3β-mediated pathway [37]. Down-regulation of NR1 mRNA could be
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explained since estrogen receptor-α, when bound by its ligand E2, facilitates NMDA
receptor subunit gene expression by recognizing palindromic DNA sequences [58]; thus,
E2 has a direct genomic role in NMDA receptor subunit expression. Additionally,
response element binding of estrogen receptor-α relies on GSK-3β phosphorylation and
this phosphorylation is inhibited by lithium [37] since lithium is a selective inhibitor of
GSK-3β [26]. I chose such high concentrations for E2 and LiCl based on the literature,
since 10mM LiCl inhibits ~70% GSK-3β protein activity [52], and a 0.04µM
concentration of E2 significantly increases bcl-2 expression – an anti-apoptotic protein –
via calcium influx in cell cultures [59]. Medunjanin et al. [37] used MELN cells treated
for 48 h with 30mM LiCl which decreased estrogen receptor-α response element binding
and this decrease was the result of GSK-3β inhibition. The aforementioned references
provide insight into my results since LiCl significantly decreased NR1 mRNA expression
in E2-treated cortical (see figure 2A) and hippocampal cultures (see figure 2B) after 48 h
treatment period. Since NR1 mRNA in E2-treated cells did not change, I deduce this
reduction is the result of LiCl (potentially via inhibition of GSK-3β activity). Whether or
not LiCl influences estrogen receptor-α/GSK-3β-mediated pathway within my
experimental parameters still remains to be elucidated.

I am currently working on

experiments to test these effects. Studies on NR1 protein level should be conducted
under my experimental and treatment conditions. Present results are represented in
mRNA expression and post-transcription and/or post-translational influences may render
differences at the protein level when compared. Both estrogen and lithium alter the
phosphorylation state of NMDA receptor subunits reducing NMDA receptor-mediated
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excitotoxicity [13, 19, 34]. It will be interesting to note the phosphorylated state of
NMDARs within my experimental parameters; however, within the scope of this project,
I provide substantial evidence on that combined E2/LiCl alter excitotoxicity and NR1
mRNA expression.

Excitotoxicity mediated by NMDA receptor characterizes many neurological
diseases [see 33].

The E2 concentration I chose for my experimental procedures

(0.04µM) also provides neuroprotection for hippocampal cultures [9], and as mentioned,
increases bcl-2 expression [59].

A concentration of 0.04µM E2 should provide

neuroprotection against excitotoxicity, however, glia may respond differently to this
treatment. After pre-treating primary cultures for 48 h with E2 and/or LiCl I exposed
these glial cultures to a toxic level of glutamate for 1 h. Cortical cultures displayed
higher viability with LiCl treatment compared with hippocampal cultures (see figures 3B
& C). NR1 (see figure 2B) and NF-H mRNA expression (see figure 1D) were higher in
hippocampal cultures than cortical cultures (see figure 1B & 2A). These observations
could explain the extremely low viability in treated hippocampal cultures (see figure 3B)
since excitotoxicity is mediated via NMDA receptor signaling. The literature indicates
that E2 and lithium affect NMDA receptor, but with opposing actions. On the one hand,
estrogen facilitates NMDA receptor-regulated calcium influx [59], but studies show
estrogen’s neuroprotective qualities against glutamate insult are through calciumindependent pathways [47]. On the other hand, lithium reduces calcium influx and
NMDA receptor-mediated glutamate excitotoxicity [10, 18].

Normally, inducing

excitotoxicity reduces viability among neuronal cultures, but glia are more tolerant to this
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insult [see 35].

My cortical cultures exhibited high glia-associated GFAP mRNA

expression (figures 1A). Although hippocampal cultures showed this as well (see figures
1C), hippocampal cultures also expressed higher levels of neuron-associated NF-H
mRNA expression compared with cortical cultures (see figures 1B & D). Results from
FDA/PI assay (figures 3A-C) strengthen densitometric data since cortical and
hippocampal cultures tolerated excitotoxicity as observed with Control, which was not
significantly affected by such a high dosage of glutamate (see figures 3A-C). Cortical
cultures expressing higher levels GFAP mRNA (see figure 1A) also explain increased
cell viability in Control and LiCl-treated cortical cultures (see figure 3B).

Treated

hippocampal cultures (figure 3B) did not display this protective quality since
hippocampal cultures also expressed higher levels of NF-H mRNA (see figure 1D).

Previous literature specifies that both estrogen and lithium act as neuroprotective
agents and may be used as a palliative treatment for neurodegeneration [10, 15, 51]. My
study is the first to show that combined E2 and LiCl affect NR1 mRNA expression and
excitotoxicity in cortical and hippocampal primary mixed brain cell cultures. Studies of
this caliber are wanting since little is known about how E2 and LiCl influence molecular
processes of the brain.

Analysis of NMDA receptor subunit mRNA and protein

expression using post-mortem Alzheimer’s disease (AD) brains show a decrease in NR1
and NR2B in the hippocampal formation with advancement of the disease [38]. In a
study using ovariectomized rats, estrogen-replacement did not affect NMDA receptor
subunit mRNA expression; although, duration of ovariectomy did affect this expression
[1]. In recent years, post-menopausal women are diagnosed with AD more often than
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men and this statistic is related to estrogen deficiency [14]. Estrogen replacement therapy
(ERT) proves to be beneficial to post-menopausal women in reducing the risk of
developing AD [see 14].

Studies demonstrate that the dominant form of estrogen,

estradiol, plays an important role in neuroprotection and enhancement of learning and
memory [20]. The use of ERT is a subject of debate due to the risk of developing breast
cancer.

This is marked by an increased incidence of lobular carcinoma in post-

menopausal women under ERT [42] and women suffering from depression during periand post-menopause are often prescribed lithium [4, 29]. Estrogen and lithium also
affects the dopamine pathway, a pathway implicated in many clinical disorders and
neurodegenerative diseases [40, 54].

An increase in dopaminergic pathways is a

characteristic of bipolar disorder (manic-depression) and lithium is readily prescribed as a
prophylactic for this disorder [54]. Studies show that combined E2/LiCl alter serotonin
and dopamine metabolites. Ovariectomized rats treated with E2 show no change in
frontal cortices levels of serotonin, dopamine or dopamine metabolites. When E2 is
combined with LiCl, though, dopamine is greatly decreased but show higher levels of
serotonin and dopamine metabolites [39].

Additionally, NMDA agonist increase

dopamine release modulated by hormones [5]. It will be worth studying the involvement
of combined E2 and LiCl in the dopamine pathway and how these two agents affect
NMDA receptor expression and function. An understanding of underlying molecular
mechanism in regards to how E2 and LiCl interact is lacking.

The present study

introduces and advances perspectives for additional studies directed towards developing
palliative therapies for neurodegeneration and postmenopausal-related cognitive decline.
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CHAPTER II
Combined Estradiol and Lithium Chloride Specifically Alter Factors Involved in
Learning, Memory, but not Neuroprotection in Primary Cultures

Abstract
Estrogen replacement therapy (ERT) is commonly prescribed during menopause. Postmenopausal women also tend to suffer from depression and as a result are prescribed
antidepressants – in addition to ERT. Glia are the dominant brain cell type but little is
known about how the combination of hormones and antidepressants affect glia.
Investigations show that both hormones and antidepressants facilitate gene expression.
The paucity of data on how combined hormones and antidepressants interact in regulating
gene expression led me to hypothesize that in primary cultures of mixed brain cells
predominated by glia, combined 17β-estradiol (E2) and lithium chloride (LiCl) (E2/LiCl)
will alter mRNA expression of markers involved in synaptic plasticity and
neuroprotection. I recently published that 48 h treatment of E2/LiCl reduces glutamate
receptor subunit mRNA expression and increases excitotoxicity in primary cultures of
mixed hippocampal and cortical cells predominated by glia. In the present study, I
quantified mRNA expression of BDNF, Bcl-2 and ER-α using the cDNA of treated
primary cultures of mixed brain cells from the previous chapter. Results indicate that a
48 h treatment period with combined E2/LiCl significantly increases BDNF and ER-α
mRNA expression compared with Control and E2 treatment alone. Increased ER-α
mRNA expression, however, was culture specific – e.g. an increase in hippocampal but
not cortical cultures. No significant differences were noted for Bcl-2 mRNA expression,
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though.

These results add to the literature that combined hormones (E2) and

antidepressants (LiCl) alter gene transcription of factors involved in learning and
memory.

2.1 Introduction
Estrogen replacement therapy (ERT) is a common prescription for menopause,
specifically during post-menopausal stages. Depression is common during menopause
and as a result, women are prescribed antidepressants in combination with ERT [5, 27].
It is unfortunate that few studies focus on the interacting properties of hormones and
antidepressants since both influence a myriad of cell signaling pathways [23, 31].
Estrogen is the main constituent diminished during menopause [2] and this depletion not
only affects women physiologically but also has neurological implications [12]. Studies
show that estrogen depletion influences astrocytosis, cell proliferation and differentiation
of neurons [41]. A plethora of protein signaling cascades are facilitated by estrogen and
these interactions result in gene expression of markers involved in cell survival, learning
and memory among glia and neurons [31]. The two receptors for estrogen are estrogen
receptor α and β (ER-α and ER-β) and these receptors play a role in facilitating estrogenmediated glial [9] and neuronal [31] protein signaling cascades. Studies also show the
co-expression of brain derived neurotrophic factor (BDNF) and ER-α among pyramidal
cells of rat hippocampus [45], but BDNF drastically decreases in people suffering from
neurodegenerative disorders [44]. Although BDNF expression is noted primarily among
neurons [19], BDNF is also shown to be co-expressed among glia in rat cortical and
hippocampal areas [39] and in mouse primary glia cultures [21]. Estrogen, via ER-α,
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increases BDNF expression and facilitates BDNF-tyrosine kinase receptor signaling in
both glia and neurons [44]. Anti-apoptotic factors are also affected by ER-α. Astrocytic
co-expression of B-cell lymphoma/leukemia-2 (Bcl-2) and ER-α in the hippocampus of
post-mortem brains of Alzheimer’s disease (AD) patients indicates a potential mechanism
for ER-α neuroprotection [9, 29].

Additionally, ER-α expression increases in AD

patients compared with controls [29].

Lithium is commonly used to treat bipolar disorder, and it is now over a decade
since lithium was identified as a specific inhibitor of glycogen synthase kinase-3beta
(GSK-3β) [25], and molecular implications for lithium continue to be explored. Similar
to estrogen, lithium facilitates gene expression responsible for anti-apoptosis, learning
and memory [30]. Lithium indirectly facilitates gene expression by interacting with
GSK-3β, an enzyme highly involved in development, gene expression, and cell signaling
regulation as reviewed by Grimes and Jope [15].

Among neurons, lithium-GSK-

3β inhibition is associated with reducing apoptosis [20], increasing neurotrophic factors
[1], and facilitating DNA binding of transcription factors [14, 37]. Lithium also affects
astrocytic pH levels that stimulate myo-inositol transport systems, ultimately affecting
protein signaling pathways in astrocytes [46]. Inositol signaling is known to be regulated
by proline-, glutamic acid-, and leucine-rich protein-1 (PELP1), a co-regulator of ER-α
signaling [35].
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There is a paucity of studies on how various treatments interact with one another
(through physiological and/or molecular processes).

I recently published a study

focusing on combined effects of estradiol (17β-estradiol; E2) and lithium chloride (LiCl)
(E2/LiCl) on glial NMDAR subunit NR1 gene expression and glutamate excitotoxicity. I
showed that a 48 h E2/LiCl treatment reduced NR1 gene expression and increased
glutamate excitotoxicity in mouse hippocampal and cortical primary cultures of mixed
brain cells predominated by glia [48]. In the present study, I use the same cDNA from
treated primary cultures of mixed brain cells from previous chapter to further investigate
how combined E2/LiCl influence gene expression. Both estrogen and lithium directly
and/or indirectly influence gene expression of factors involved in learning, memory and
neuroprotection [23, 31], which led me to hypothesize that combined E2/LiCl will alter
BDNF, Bcl-2, and ER-α mRNA expression in these cultures. My results indicate that a
48 h E2/LiCl treatment increases BDNF, ER-α mRNA, but not Bcl-2 mRNA expression
in mouse primary mixed cultures. I also note that these results differed according to
culture type (hippocampal versus cortical cultures). My data does present developmental
differences since results are generated from embryonic brain cell cultures. Still, I believe
my results will help elucidate interactions of hormones and antidepressants and how they
affect gene expression of proteins involved in learning, memory and neuroprotection.
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2.2 Experimental Procedures
2.2.1 Primary Mixed Brain Cell Cultures, Chemicals and Treatment
For a detailed description of experimental procedures, refer to the previous
chapter. Briefly, primary mixed hippocampal and cortical cultures were harvested from
E18.5 C57BL/6J mice. Disassociated cells were randomly plated (6 x 106 for cortical
cultures and 3 x 106 for hippocampal cultures) on poly-D-lysine (100µg/mL; SigmaAldrich, Missouri) coated 12-well plates containing B27/Neurobasal medium (Invitrogen,
California) with 0.5mM L-glutamine and 4µg/mL gentamicin. Cells were maintained in
a humidified, 5% CO2 atmosphere incubator with a set temperature of 37°C. Additional
12-well plates, with poly-D-lysine (100µg/mL) coated coverslips were set aside for
immunocytochemical purposes. After 4 days in culture, the media was removed entirely
and replaced with fresh media; half of the media was changed every 4 days, thereafter,
until E2 and/or LiCl treatment. After twelve days in culture, the media was removed
entirely and replaced with media treated with 10mM LiCl (Sigma-Aldrich, Missouri),
0.04µM E2 (Sigma-Aldrich, Missouri), or combined E2/LiCl and duration of treatment
for each group was 48 h.

2.3 Experimental Techniques
2.3.1 Immunocytochemistry
Primary mixed cultures were immunolabeled using neurofilament-H (NFH) (Upstate, Virginia) and glia fibrillary acidic protein (GFAP) (Sigma-Aldrich,
Missouri) antibodies. Cells were fixed for 15 minutes at 4°C with ice-cold 4%
paraformaldehyde/4% Sucrose/DPBS and permeabilized for 30min at room
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temperature with 0.25% DPBST (DPBS with 0..25% [v/v] Triton X-100). Nonspecific binding sites blocked with 10% normal goat serum/DPBS overnight at
4°C. Primary antibodies were then incubated at room temperature with mouse
NF-H or GFAP antibodies and visualized using fluorescent-conjugated secondary
antibodies (directed against the host of the 1° antibody).

Cells were

counterstained with Hoechst to reveal nuclei, coverslips were mounted on glass
slides, and sealed with clear nail polish. Images were captured using a Leica
Leitz DM RB fluorescent microscope with a Leica DM 500 camera (Leica,
Bannockburn, IL, USA).

2.3.2 Total RNA Isolation and cDNA Synthesis
Total RNA was isolated from cultures after treatment with TRIzol reagent
(GIBCO, California), according to manufacturer’s protocol. Briefly, cultures were rinsed
with ice-cold DPBS, TRIzol Reagent (600µL-1mL) was added directly into each well,
and then homogenized. Homogenized cells were then transferred to a fresh tube, and
incubated at room temperature. Chloroform was added and centrifuged at 6, 700 x g at
4°C.

Total RNA (aqueous phase) was transferred to a sterile tube and allowed to

precipitate with isopropanol and glycogen overnight at -20°C. The RNA was pelleted via
centrifugation at 6, 700 x g at 4°C, supernatant decanted and RNA pellet was washed
twice with 75 % ethanol. Pellets were then air dried and resuspended with DEPC-treated
water.

The DNA contaminants were removed with the RQ1 DNase kit (Promega,

Wisconsin). Total RNA was then reverse transcribed (RT) using SUPERSCRIPTTM II
RNase H-free reverse transcriptase (Invitrogen, California), according to the
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manufacturer's protocol.

Briefly, 500ng of total RNA was reverse transcribed with

0.05µg/µl of Oligo (dT)12-18 at 65°C for 5 minutes. First strand cDNA was synthesized
with 5mM MgCl2, 10mM DTT, and 2.5 units Superscript II and incubated at 42°C for 50
minutes; reaction was terminated at 70°C for 15 minutes.

RNase H (Invitrogen,

California) was added once the first strand was synthesized to remove any remaining
RNA by incubated at 37°C for 20 minutes.

2.3.3 Quantitative Real Time RT-PCR
First strand cDNA was amplified via real time PCR using SYBR Green PCR
master mix (ABgene, New York), 200-300nM of forward and reverse primers using AB
7300 qPCR apparatus. Cycling parameters were set at: 95°C 15s, 57°C or 63°C 30s, and
extension at 72°C for 30s, for a total of 40 cycles, followed by a final extension at 72°C
for 10 minutes.

The specific primer pairs were: BDNF: forward primer, 5'-

ATCCAAATATGGCACAGCAA-3;

reverse

TTCTGCCTGAGTTTTGATGC-3';

Bcl-2:

AGGAGCAGGTGCCTACAAGA-3;

reverse

CCACTGTCT-3';

ER-α:

forward

primer,

primer,
forward

primer,

primer,

5'5'-

5'-GCATTTTCCCA

5'-AAGGGCAGTCACAATGAACC-3;

reverse primer, 5'-GCCAGGTCATTCTCCACATT-3'; HPRT: forward primer, 5'GGAGCGGTAGCACCTCCT-3'; reverse primer, 5'-AATCCAGCAGGTCAGCAAAG3'. All samples were compared with a standard curve comprised of pDNA of HPRT,
BDNF, Bcl-2, and ER-α generated using TOPO TA Cloning® Kit (Invitrogen,
California). Readings were normalized by dividing mRNA starting quantity (SQ) of
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BDNF, Bcl-2, or ER-α by the house-keeping gene HPRT mRNA SQ; output are in
picograms (pg) of mRNA.

2.3.4 Statistical Analysis
Data are presented as the mean ± S.E.M and statistical significances were
determined by ANOVA followed by Fisher’s least significant difference post-hoc testing.
Significant differences have a p-value < .05. All results were obtained from two separate
experimental procedures with factors and levels randomly determined.

2.4 Results
2.4.1 Combined E2/LiCl increases factors involved in learning and memory
I chose to analyze mRNA expression since both estrogen and lithium indirectly
and/or directly affect genomic responses [23, 31]. Real time RT-PCR results indicate
that BDNF, ER-α and Bcl-2 mRNA expression significantly differs depending on the
brain region (p < 0.001) – hippocampal cultures express higher levels of mRNA
compared with cortical cultures (figures 1A-1C). I also noted that combined E2/LiCl
significantly increases (p < 0.05) BDNF and ER-α mRNA expression (figure 1A and
1C). Chronic lithium does not affect Bcl-2 expression in glia [8], but I specifically
wanted to see if a short-term treatment with LiCl (48 h) will alter Bcl-2 gene expression
in my primary mixed culture predominated by glia.

Expression of Bcl-2 mRNA,

however, showed no significant differences (p > 0.4) across treatment parameters (figure
1B).
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After a 48 h treatment period E2 alone did not affect BDNF mRNA expression for
either hippocampal or cortical cultures (figure 1A). The LiCl and E2/LiCl treatment,
however, significantly increased hippocampal and cortical BDNF mRNA expression. In
cortical cultures, LiCl significantly increased (p < 0.05) BDNF mRNA expression
compared with Control, but combined E2/LiCl treatment significantly increased (p <
0.05) BDNF mRNA expression compared with both Control and E2 treated cortical
cultures (figure 1A). Hippocampal cultures also displayed this trend, except that LiCl
also increased BDNF mRNA expression compared with E2 treatment as well (figure 1A).
There were no significant differences in ER-α mRNA expression for cortical cultures
across treatments (p < 0.05) (figure 1C). The E2 treatment did not significantly alter
hippocampal ER-α mRNA expression when compared with control and, although LiCl
seemed to increase ER-α mRNA expression this was not a significant increase (figure
1C).

Combined E2/LiCl treatment, however, significantly increased (p < 0.05)

hippocampal ER-α mRNA expression after a 48 h treatment period compared with
Control and E2 treated hippocampal cultures (figure 1C). These results demonstrate that
my treatment parameters do not alter Bcl-2 gene expression and that combined E2/LiCl
treatment increases BDNF and ER-α gene expression but this increase is region-specific
for ER-α (e.g. increase seen in hippocampal cultures but not cortical cultures). This
increased gene expression is significant when compared with Control and E2 treated
cultures.

Additionally, LiCl treatment only affects BDNF gene expression.

No

significant differences in gene expression for any markers were detected with E2-treated
cultures.
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Figures 1A-C: Real time RT-PCR of BDNF (A), Bcl-2 (B), and ER-α (C) mRNA
expression. E18.5 hippocampal (grey bars) and cortical (black bars) primary cell cultures
were treated for 48 h with 0.04µM E2, 10mM LiCl, combined E2/LiCl, or Control (no
treatment). After treatment total RNA was isolated and reverse transcribed. Expression
for each gene was normalized using the house-keeping gene HPRT. The figure denotes
normalized mRNA expression in picograms (y-axis) and treatment type (x-axis). *, pvalue < .05 compared with control; #, p-value < .05 compared with E2.

2.5 Discussion
The immunocytochemical images in figure 2A clearly depict high GFAP
expression in hippocampal cultures, but still with low NF-H labeling – as noted by the
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unlabeled surrounding nuclei (figure 2B). This coincides with findings from the previous
chapter that these primary mixed brain cell cultures express high levels of glia-specific
mRNA, but with consistently low levels of neuron-specific mRNA [48]. Also, it is
noteworthy that harvesting brain cells at E18.5 rather than at E14-E15, along with the
process of mechanical trituration, promotes viable primary cultures with a predominance
of glia. Glia predominate the brain and investigations on how estrogen and lithium affect
glial molecular mechanisms are essential for developing and providing palliative
treatment regimes for post-menopausal women.

Glia are known to express similar

markers as neurons do, such as BDNF, Bcl-2, and ER-α and expression level of these
markers vary according to neuroanatomical region and developmental stage. Both BDNF
[51] and Bcl-2 [7] are highly expressed in hippocampal and cortical regions; however,
mRNA distribution of ER-α is also expressed in these brain regions but is difficult to
determine due to low expression level in these brain regions [42]. My data concurs with
the literature indicating that BDNF, Bcl-2, and ER-α mRNA are expressed in these
hippocampal cultures and cortical cultures, but higher expression is noted in hippocampal
cultures (figures 1A-1C).
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Figures 2A-2B: Immunocytochemical images of hippocampal cultures labeled with
GFAP (A; 200X) and; NF-H (B; 400X) antibodies (green). All nuclei are labeled with
Hoechst stain (blue). Image color quality and gamma adjustments were made using
Adobe Photoshop CS.

I note no significant differences in Bcl-2 gene expression across cultures and all
treatment types (figure 1B). This absence coincides with results obtained from chronic
lithium treated neuronal and glial cell lines [8]. Studies do indicate that E2 increases Bcl2 expression in primary neuronal cultures from prenatal rat hippocampus, specifically
with the concentration and treatment period used in my study [50]. Since I used cultures
expressing high GFAP levels (figure 2A), the E2 concentration Wu et al. [50] used must
not affect glia Bcl-2 expression – solely at the transcriptional level and under my
experimental parameters, though (figure 1B). Wu et al. [50] explains that the molecular
mechanisms that underlie E2 up-regulating Bcl-2 is mediated through ER-α interactions
within the Akt pathway. One potential explanation for my results is the ER-α/Akt
pathway is highly dependent on PELP1 [4] and PELP1 is expressed at lower levels in glia
[24]; there are caveats of molecular processes that may be at play, though.

In the previous chapter, I note that in E2-treated cultures LiCl reduces NMDA
subunit NR1 mRNA expression [48]. In the present study, E2 has an additive effect in
LiCl-treated cultures on BDNF and ER-α mRNA expression, however, E2 alone does not
significantly alter BDNF or ER-α expression (figure 1A and 1C). Lack of altering
mRNA BDNF or ER-α expression may be explained by the plasticity of estrogen-
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mediated signaling pathways.

Direct genomic effects are classically mediated by

estrogen bound ERs, one specific target is NMDA subunit promoter regions [49] and
transcriptional properties of ERs are facilitated by GSK-3β – a pathway attenuated by
lithium [32]. Attenuation by lithium could explain findings from the previous chapter,
but some other mechanism must be at play to explain my present findings. Estrogen
mediates indirect genomic effects by binding to ERs and non-ERs such as G-protein
coupled receptor, GPR30 [31, 38], which is shown to be expressed in rat brain [3] and
activate adenylyl cyclase resulting in cAMP production [38].

Production of cAMP

ultimately leads to the activation of the transcription factor cAMP response element
binding protein (CREB) [22]. Lithium is a well known facilitator of CREB DNA binding
properties by selectively inhibiting GSK-3β, a CREB attenuator [14], and BDNF gene
expression is mediated by CREB [17, 26]. These indirect genomic effects mediated by
estrogen may be facilitated by lithium, thereby increasing BDNF mRNA expression
(figure 1A); however, further investigation is needed to elucidate the upstream molecular
pathways involved using my experimental parameters.

The literature is dichotomous on whether lithium increases BDNF levels in the
hippocampus or not. Studies show that rats chronically treated with lithium for 2 and 4
weeks increase BDNF expression in their hippocampus [11], but Hammonds and Shim
[17] demonstrate that a 4 week lithium treatment does not alter BDNF levels specifically
in rat CA1 region of the hippocampus. There may be some developmental differences,
since Fukumoto et al. [11] used younger rats compared with Hammonds and Shim [17].
Additionally, Hammonds and Shim [17] showed BDNF expression is specific to

53

neuroanatomical regions, since they reported that lithium did increase BDNF expression
in the dentate gyrus. In my study, LiCl increased BDNF gene expression for both culture
types (hippocampal and cortical), specifically compared with Control (figure 1A), but the
literature states that astrocytic BDNF expression is not affected by lithium [16]. Guo et
al. [16] used neonatal rat primary cortical astrocytic cultures showing no effect by lithium
on BDNF expression, but lithium does increase BDNF among rat cortical neurons [18]
and my results on ER-α and BDNF mRNA expression may be influenced by the low
neuronal population in my primary mixed cultures (figure 2B; [48]). Additionally, Guo
et al. [16] treated their cultures for only 20 h which might indicate a temporal difference
in lithium treatment and BDNF expression. But the interesting note is that in the Guo et
al. study, these lithium-treated primary astrocytic cultures also expressed increased GSK3β inhibition [16].

Results indicate that although E2 or LiCl treatment does not significantly alter
ER-α mRNA levels, I note a significant additive effect by E2 in LiCl-treated
hippocampal cultures (figure 1C) that express high GFAP immunoreactivity (figure 2A).
Under conditions of neuronal damage, ER-α expression increases among neonate rat
cortical astrocytes, mediated by E2, and this increase aids neuronal damage [6]. Cortical
ER-α mRNA expression was not affected by my treatment parameters, though (figure
1C). Cortical cultures did express higher glia-specific mRNA than hippocampal [48] and
I report in the present study that primary hippocampal cultures show NF-H perikaryon
accumulation (figure 2B), which is indicative of neuronal apoptosis [28].
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Recent studies using neuronal cell lines show that ER-α gene expression has an
E2 dose dependency – reducing ER-α gene expression within 16 h treatment of 0.1µM
E2 [36]. Other studies indicate that ER-α increases in neonatal rat hippocampus with E2
treatment [40]. ER-α also raises developmental considerations since ER-α expression in
rat brain is high during prenatal day 9, declines then increases at neonate stage and then
declines again with age [47]; this occurs in both the hippocampus and cortex [13].
Cultures used in this study are from embryonic mouse brain (E18.5) and this
developmental factor may account for differences noted in other publications, but I show
no significant differences in ER-α mRNA expression with E2 or LiCl individual
treatment (figure 1C).

Studies show that combined estrogen and lithium affect the dopamine pathway, a
pathway associated with many neurodegenerative diseases [34, 43].

Stereotyped-

behavior is increased with apomorphine, a dopaminergic agonist, in ovariectomized rats
after discontinuing chronic treatment of estrogen; but this increase in stereotypedbehavior is diminished with lithium [10]. Additionally, ovariectomized rats treated with
combined E2 and LiCl show greatly decreased dopamine levels, but show higher levels
of serotonin and dopamine metabolites in the brain [33].

Results presented in this

chapter are generated and interpreted at the transcriptional level but these results indicate
that some molecular mechanism is being altered as a result of my treatment paradigm.
Many brain cell signaling pathways are facilitated by both estrogen and lithium and both
seem to affect similar pathways. One common element that both estrogen and lithium
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possess is an interaction with GSK-3β since lithium affects estrogen receptor–mediated
cell signaling via GSK-3β inhibition [32]. Evidence showing that combined estrogen and
lithium affect GSK-3β and dopamine pathways postulate some underlying interaction
between estrogen and lithium that affect brain cell signaling pathways. Knowledge on
how estrogen and lithium interact at the molecular level will contribute to providing
proper treatment regiments for women undergoing ERT while displaying symptoms of
depression.
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CHAPTER III
Lithium Enhances Episodic Memory and the Expression of Factors Involved in Learning,
Memory and Anti-Apoptosis in Estrogen-Deficient Mice

Abstract
The hippocampus and cortex are areas of the mammalian brain that are involved
in learning and long-term memory, respectively. Also, there is a tendency for learning
and memory to decline in adult women during peri- and post-menopausal periods. Both
estrogen and lithium affect learning and memory processes and both of these agents may
be prescribed to post-menopausal women; however, the literature shows that hormone
therapy is correlated with an increased incidence of breast cancer. I hypothesized that in
estrogen-deficient mice lithium alone will enhance behavioral task performance, and in
the brain, increase expression of factors involved in learning and memory. My study
used bilaterally ovariectomized (bOVX) C57BL/6J mice treated for one month with
14.2mM lithium chloride (LiCl) in their drinking water. Results indicated that LiCltreated bOVX mice enhanced their performance in an object recognition task (ORT)
compared with non-treated bOVX. Enhanced performance in ORT led me to examine in
the hippocampus and cortex, expression of mRNA and related proteins involved in
learning, memory and neuroprotection. Gene expression of these factors are increased in
the cortex of LiCl-treated bOVX mice, but not in the hippocampus, compared with nontreated bOVX mice.

A glutamate receptor subunit and neurotrophic factor protein

expression increased in the hippocampus of LiCl-treated bOVX mice compared with
non-treated bOVX mice.

Additionally, increased protein and mRNA expression
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coincided with increased inhibition of a kinase involved in attenuating expression of
markers relevant to learning, memory and neuroprotection. I believe my study may be
useful in developing palliative therapies that use lithium as a treatment for cognitive
decline associated with estrogen-deficiency (e.g. post-menopause).

3.1 Introduction
A lack of circulating estrogen during peri-menopause is correlated with cognitive
decline [29]. Hormone therapy is usually prescribed during peri- and post-menopause,
but increased breast cancer incidences are reported for women undergoing hormone
therapy

[31].

Scientific

investigations

do

indicate

that

estrogen-mediated

neuromechanisms enhance synaptic plasticity [25], reduce apoptotic activity in cortical
neurons [21], regulate brain derived neurotrophic factor (BDNF) [40], and facilitate
transcription factor activation such as cyclic adenosine monophosphate (cAMP)
responsive element binding protein (CREB) [27].

Estrogen stimulates molecular

processes involved in learning and memory; however, hormone therapy does not improve
cognitive decline during menopause, specifically episodic memory [20]. Ovariectomized
(OVX) and estrogen receptor-α (ER-α) knockout mice perform poorly on hippocampaldependent behavioral tasks indicating that normal circulating estrogen and ER-α
expression influence cognitive-behavioral performance levels [11]. Co-localization of
ER-α and BDNF are noted in pyramidal cells of the hippocampus, and estrogen
influences BDNF expression [40].

Ligand binding of BDNF to tyrosine receptors

initiates a signaling cascade that results in activating CREB [3], increasing synaptic
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plasticity [43], and facilitating CREB-mediated gene expression via N-methyl-D-aspartate
receptor (NMDAR) signaling pathways [47].

Lithium is commonly prescribed for bipolar disorder and schizophrenia [10], but
lithium also affects several molecular pathways via glycogen synthase kinase-3beta
(GSK-3β) inhibition [24].

Inhibition of GSK-3β reduces apoptotic activity [22],

increases neurotrophic factors [2], and facilitates CREB’s response element binding [15,
33]. Though the mechanism remains elusive, the literature states that lithium inhibits
GSK-3β through indirect and direct mechanisms. Indirectly, lithium promotes protein
kinases that inhibit and may simultaneously inhibit phosphatases that activate GSK-3β
[24].

Lithium directly inhibits GSK-3β by acting as a competitive inhibitor of

magnesium, magnesium being co-factor for ATP in GSK-3β activation [36]. Aside from
lithium’s inhibitory action on GSK-3β, lithium acts as neuroprotectant by indirectly
influencing NMDAR signaling. Lithium decreases NMDAR-mediated excitotoxicity by
reducing phosphorylation/activation of Src tyrosine kinases thus inhibiting NMDAR
subunit signaling pathways [18]. The neuroprotective properties of lithium are also
marked by increased levels of the anti-apoptotic agent B-cell lymphoma/leukemia-2 (Bcl2) and BDNF [5]. Estrogen also facilitates Bcl-2 expression by the CREB activation
pathway and by indirectly interacting with NMDAR [50].

Estrogen and lithium influence similar signaling transduction pathways;
specifically facilitating molecular signaling pathways involved in learning and memory
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[15, 27]. Chapter one experimental data showed that combined estrogen and lithium
chloride (LiCl) treatment reduces mRNA expression of NR1, a critical subunit of
NMDAR, in primary mixed brain cell cultures, predominated by glia [42], indicating
interaction between estrogen and lithium in genetic expression.

A former master’s

degree graduate from the laboratory of my advisor, Dr. Ophelia I. Weeks, showed that
14.2 mM LiCl in drinking water maintains a sub-therapeutic plasma level of lithium at
about 0.2 mM and facilitates enhanced performance in spatial and non-spatial memory
tasks (unpublished data). In the present study I hypothesized that LiCl-treated estrogendeficient mice will perform better in an object recognition task (ORT) by altering
mRNA/protein expression of factors involved in learning, memory and neuroprotection
in the hippocampus and cortex. To test my hypothesis I treated bilaterally OVX (bOVX)
C57BL/6J mice with 14.2 mM LiCl for 1 month. Results presented in this chapter
indicate that LiCl treatment enhances ORT performance in bOVX mice and this
enhancement coincides with an increase in factors involved in learning, memory and
neuroprotection.

Typically, women undergo natural menopause by their late 40s to early 50s and
estrogen replacement therapy (ERT) is commonly prescribed peri- and post-menopause.
Post-menopausal women on ERT may be at risk, since there is increased incidences of
lobular carcinoma in women undergoing ERT [31].

Selective estrogen receptor

modulators (SERMs) provide an alternative to ERT but studies show that SERMs do not
improve cognitive functioning [30, 34]. Therefore, an alternative therapy for peri- and
post-menopausal women is wanting.

The present study will contribute data to the
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literature on lithium’s potential as a therapeutic agent for enhancing cognitive function
during a period of estrogen-deficiency.

3.2 Experimental Procedures
3.2.1 Subjects, Surgery and Treatment
C57BL/6J female mice (n = 20) were purchased from Jackson Laboratories.
Animals were kept in an environment of 20-22°C temperature, 60% humidity, within
polycarbonate transparent cages (26.7cm X 20.6cm X 14cm) on a 12-hour day-night
cycle with free access to water and food.

The Institutional Animal Care and Use

Committee approved all experiments (08-017).

At 4.5 months of age mice were anesthetized with ether, weighed, and both
ovaries were removed surgically. Mice were positioned dorsal side up and for each
surgical procedure, parallel to the long axis of the animal’s body, an incision ¾ cm in
length was made ½ cm from the hip area. The fallopian tube was located bilaterally and
both ovaries were removed.

Treatment with 14.2mM LiCl + 0.9% Saline in their

drinking water began at 5 months of age for 1 month; LiCl at 14.2mM maintains lithium
blood content at a sub-therapeutic range (< 0.5 mM) [37]. The control group received
only 0.9% Saline in their drinking water. All animals were divided into four groups
(lithium-treated bOVX and Sham; saline-treated bOVX and Sham). Mice were handled
for 15-30 s weekly and weighed weekly. After a one-month treatment period, mice were
subjected to a cognitive-behavioral task (e.g., ORT).
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3.2.2 Object Recognition Task (ORT), Thigmotaxis and Velocity
Studies using ORT indicate that animals habituate to an object and when
subsequently introduced to a different, novel object these animals will spend greater
lengths of time with the novel object [32]. In addition, ORT is known to be highly
dependent upon the hippocampus [44, 48] and is a form of episodic memory. The ORT
were performed in an arena measuring 121 cm in diameter, with a depth of 22cm. The
arena was painted white and the flooring covered with bedding material. Two strips of
Velcro, 60cm apart were placed on the bottom of the arena to secure each object. There
were three objects in total: two oval/egg-shaped objects (Old) and one pyramid object
(New). All objects were of the same color and size, made of the same material, by the
same manufacturer (Playskool®). All objects were wiped with 95% ethanol between
trials. Twenty-four hours (24 h) prior to each treatment regime, 3-5 experimental mice
were allowed to run freely in the empty arena (no objects) for 30 min to introduce
olfactory cues to the testing arena.

After olfactory habituation, each mouse was

individually exposed to two identical objects (egg shaped), for ten minutes (priming).
After priming, the subject was rested for thirty minutes and then tested on novel object
recognition for ten minutes. During this portion of the test, one of the two old objects
was replaced with a new pyramid object (positioning of objects was randomized). These
last ten minutes were videotaped using a Panasonic digital camera and analyzed with the
tracking system EthoVision XT (version 5.0 Noldus Information Technology, Leesburg,
VA) to measure ORT, thigmotaxis to measure anxiety and velocity to measure speed.
Parameters for ORT were measured when the subject came within 5cm of the new object,
and/or investigated the new object. Measurements were calculated and presented as a
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percentage, based on the following calculation, the novel object/(novel object + old
object). Thigmotaxis measures anxiety displayed by the experimental mice. Anxiety was
characterized as time spent 5cm from the edge of the arena, defined as the thigmotactic
zone, distinguishable from the ORT zone, the inner area with a diameter of 116cm (the
total diameter being 121cm). Velocity was measured as the average speed (cm/sec) of
experimental mice. A baseline measurement for each parameter (ORT, thigmotaxis and
velocity) was taken using non-experimental mice (n = 3).

3.2.3 Uterine and Bone Weight
All mice were anesthetized under ether and were then cervically dislocated.
Brains, uteri, femora and humeri were removed from each experimental mouse. Each
uterus was weighed and inspected to assure complete removal of ovaries during bOVX
surgery. Bones were dried at 70°C for 24 h and then weighed.

3.2.4 Total RNA Isolation and Reverse Transcription (RT)
After ORT, total RNA was isolated from brain tissue using TRIzol reagent
(GIBCO, California), according to manufacturer’s protocol.

Briefly, brains were

removed from each subject, the cortex and hippocampus of each hemisphere were
isolated under a dissecting microscope, weighed, and rinsed with Dulbecco’s Phosphate
Buffer Saline (DPBS). A 1:10 weight TRIzol reagent was added then homogenized with
an IKA homogenizer (speed 5 for 10 s). Chloroform was added and centrifuged at
12,000 x g for 15 min at 4°C. After phase separation total RNA (aqueous phase) was
collected and the protein (phenol phase) was stored at -80°C for further processing (see
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Protein isolation and Western Blot section). Total RNA was then precipitated with
isopropanol and RNA was pelleted via centrifugation. Total RNA pellet was washed
with 75 % ethanol and then resuspended in DEPC-treated water. To remove any DNA
containments RQ1 DNase kit (Promega, Wisconsin) was used. Aliquots of samples were
used for concentration and purity quantification using absorptions at 260 nm and 280 nm.

First strand cDNA synthesis was performed using SUPERSCRIPTTM III RNase
H-free reverse transcriptase (Invitrogen, California), according to manufacturer's
protocol. Briefly, 3 µg of total RNA was reverse transcribed with 0.05µg/µl of Oligo
(dT)20 at 65°C for 5 min. First strand cDNA was synthesized with Superscript III/RNase
OUT Enzyme mix and incubated at 50°C for 50 min; reaction was terminated at 85°C for
5 min. RNase H (Invitrogen, California) was added once first strand was synthesized to
remove any remaining RNA. RNase H was incubated at 37°C for 20 min. Samples were
stored at -20°C until further processed.

3.2.5 Quantitative Real Time RT-PCR
First strand cDNA was amplified via real time PCR using SYBR Green PCR
master mix (ABgene, New York), 200-300nM of forward and reverse primers using AB
7300 Real Time PCR system. Cycling parameters were set at 95°C for 30 s, 57°C - 63°C
for 30 s, and extension at 72°C for 30 s, for a total of 40 cycles, followed by a final
extension at 72°C for 10 min. The specific primer pairs were: ER-α: forward primer, 5'AAGGGCAGTCACAATGAACC-3;

reverse

primer,

5'-

GCCAGGTCATTCTCCACATT-3'; NMDAR subunit NR1: forward primer, 5'-
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ACTCCCAACGACCACTTCAC-3;

reverse

GTAGACGCGCATCATCTCAA-3';

Bcl-2:

AGGAGCAGGTGCCTACAAGA-3;

reverse

primer,
forward
primer,

primer,

5'5'-

5'-GCATTTTCCCA

CCACTGTCT-3'; BDNF: forward primer, 5'-ATCCAAATATGGCACAGCAA-3;
reverse primer, 5'-TTCTGCCTGAGTTTTGATGC-3'.

The endogenous control was

HPRT: forward primer, 5'-GGAGCGGTAGCACCTCCT-3'; reverse primer, 5'AATCCAGCAGGTCAGCAAAG-3'. All samples were compared with a standard curve
comprised of pDNA generated using TOPO TA Cloning® Kit (Invitrogen, California).
Readings were normalized by dividing interest gene number of copies by the housekeeping gene (HPRT) number of copies; output is the ratio mRNA number of copies
(described in the previous chapters as starting quantity).

3.2.6 Protein Isolation and Western Blot
Protein isolation from TRIzol after DNA precipitation was performed according
to manufacturer’s protocol.

Briefly, protein was precipitated with isopropanol,

centrifuged at 10000 x g for 10 min, and pellet washed several times with 0.3M guanidine
hydrochloride/95% ethanol. Pellet was resuspended in 1% SDS and stored at -20°C until
further processing. A Bradford assay was used to determine protein concentration of
cortical and hippocampal lysates and calculated for 20 µg/lane. Samples were diluted in
non-reducing sample buffer (0.3 M Tris-HCl [pH 6.8]; 2% SDS; 10% Glycerol; 0.01%
bromophenol blue) and boiled at 100°C for 5 min. Protein samples were separated by
molecular weight with an 8%-16% SDS polyacrilamide gel and transferred onto a
nitrocellulose membrane using XCell II Blot Module (Invitrogen, California). Non-
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specific binding sites were blocked overnight at 4°C with 5% non-fat dry milk in TBST
(TBS with 0.1% [v/v] Tween-20) and immunolabeled at room temperature for 1.5 h using
antibodies against: BDNF (Santa Cruz Biotechnology, California) and; NMDAR subunit
NR1, Phospho-CREB (serine 133), and Phospho-GSK-3β (serine 9) (Cell Signaling,
Massachusetts).

Membrane was then incubated at room temperature for 1 h with

secondary horseradish peroxidase-conjugated antibodies (directed against the host of the
1° antibody); signal enhanced with LumiGLO (Cell Signaling, Massachusetts) and
developed/visualized using x-ray film. Membranes were stripped with 0.2 M Glycine
(pH 2.5) and 0.1% (v/v) Tween-20 and labeled with anti-actin (Sigma-Aldrich, MO) –
used as a loading control. Images of x-ray films were scanned using a CanoScan Lide 30
scanner (Canon).

3.2.7 Statistical Analysis
The data are presented as mean±S.E.M and statistical significance is determined
by ANOVA followed by LSD post-hoc procedure. Significant differences have p-values
< 0.05.
3.3 Results
3.3.1 Removal of ovaries from mice resulted in weight gain
During pre-bOVX all mice weighed on average 22.0g. Throughout post-bOVX
and treatment period, mice were handled and weighed weekly prior to ORT. The average
weekly weight showed that both Sham groups (non-treated and LiCl-treated Sham)
roughly weighed the same (23.6g); however, LiCl-treated bOVX (25.5g) weighed less
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than non-treated bOVX (27.0g). Statistical analyses on weekly weight indicated that
non-treated bOVX significantly weighed more (p < 0.05) than non-treated Sham and
LiCl-treated Sham during week 1, 2, 4, and 5 – week 3 the significant difference lies
solely compared with non-treated Sham (figure 1). Weight gain for LiCl-treated bOVX
mice fluctuated since weight gain was not apparent during week 3 and 5 in LiCl-treated
bOVX compared with both Sham groups – there was also no difference during week 1
when LiCl-treated bOVX were compared with LiCl-treated Sham (figure 1). I also
monitored the daily volume intake of the treatment (or control) that indicates the average
intake of LiCl-treated water (21.7mL/day/mouse) was slightly less than saline treated
water (24.4mL/day/mouse), but this difference was not significant (p > 0.05).

3.3.2 An increase of episodic memory by LiCl in estrogen-deficient mice
Cognitive decline is a common characteristic of estrogen-deficiency as measured
by behavioral tasks [11]. Figure 2A shows that non-treated bOVX animals showed
decreased performance in ORT compared with the baseline group and the other three
experimental groups. Statistical analysis of ORT indicated that LiCl-treated bOVX mice
showed a significant increase (p < 0.05) in novel object recognition performance when
compared with non-treated bOVX (figure 2A). The LiCl-treated Sham group showed a
13% increase in novel object recognition compared with non-treated bOVX, but this
proved to be non-significant (p > 0.05). I also measured thigmotactic behavior and
velocity showing that experimental mice displayed less anxiety (figure 2B) and speed
(figure 2C), respectively, compared with baseline. These parameters, however, showed
no significant changes across treatment groups.

72

1.

Weekly Weight
30.0

Weight (g)

28.0

bOVX

26.0
24.0

*,
#
*,
#

*,
#

*,
#

*

*,
#

Sham

*

*

bOVX+LiCl
Sham+LiCl

*

22.0
20.0
Week1

Week2

Week3

Week4

Week5

Figure 1. Weekly weight of experimental mice. *, significant increase compared to
bOVX; #, significant increase compared to bOVX + LiCl.
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Sham + LiCl

Figures 2A-2C. Performance level on ORT (A), thigmotaxis (B) and velocity (C) using
EthoVison XT (see Experimental Procedures section). Baseline performance is indicated
by the black line across the graphs. *, significant increase performance compared with
non-treated bOVX.

3.3.3 Bones and Uteri
Osteoporosis and uterine atrophy are pathological characteristics of estrogendeficiency [13]. I analyzed dry bone weight from experimental mice and noted no
significant differences between non-treated and LiCl-treated groups or between bOVX
and Sham (figures 3A). Uterine weight was significantly less in bOVX (non-treated and
treated) compared with Sham (non-treated and treated), but no significant differences
between treatment groups were noted (figures 3B).
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Figures 3A-3B. Bone (A) and Uterine weight (B). *, significant increase compared to
bOVX; #, significant increase compared to bOVX + LiCl.
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3.3.4 Altered levels of Bcl-2, BDNF, ER-α and NR1 by LiCl in estrogen-deficient mice
Since LiCl increased episodic memory in bOVX mice according to ORT analysis
(figure 2A), I hypothesized this enhanced performance was caused by increased
expression of mRNA and proteins involved in learning, memory, and anti-apoptotic
activity in the brain. Figures 4A-4D shows that overall mRNA expression of ER-α, NR1,
Bcl-2 and BDNF differed between the hippocampus and cortex – ER-α and NR1
expressed higher in the cortex, and Bcl-2 and BDNF expressed higher in the
hippocampus. Statistical analysis suggest LiCl-treated bOVX mice show significant
increases (p < 0.05) in cortical mRNA expression of these genes, but with no significant
differences in hippocampal mRNA expression across treatment groups (figures 4A-4D).

Once bound by estrogen, ER-α facilitates NMDAR subunit expression via
response element binding [46] and ER-α response element binding is attenuated by
lithium [28]. LiCl-treated bOVX mice show significantly enhanced (p < .05) cortical
ER-α mRNA compared with non-treated bOVX and Sham (figure 4A). Cortical NR1
mRNA of LiCl-treated bOVX significantly increased (p < .05) compared with Sham and
LiCl-treated Sham, but not in non-treated bOVX (figure 4B). Lithium influences Bcl-2
activity through BDNF signaling cascade [38], a signaling pathway that is also affected
by estrogen [27]. Figures 4C and 4D show that LiCl treatment significantly elevates Bcl2 and BDNF cortical mRNA levels (p < .05) in bOVX mice compared with non-treated
bOVX, Sham and LiCl-treated Sham. Cortical BDNF mRNA levels are also significantly
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higher (p < 0.05) in Sham and LiCl-treated Sham compared with non-treated bOVX
(figure 4D).

Although the hippocampus showed no increase in genetic expression I wanted to
see if protein levels were altered. I used TRIzol reagent to obtain total RNA and protein
from each case study to avoid any discrepancies that might occur if RNA and protein
were isolated from different subjects (see Experimental procedures). I analyzed NR1and
BDNF expression and noted that in the hippocampus of LiCl-treated bOVX mice NR1
and BDNF protein expression increased compared to non-treated bOVX mice (figures 5A
and 5B). An increase in NR1 was also noted in LiCl-treated bOVX mice compared with
both Sham groups (figure 5A) – this increase was not noted for BDNF, though (figure
5B).

3.3.5 Phosphorylated GSK-3β levels are altered by LiCl
Lithium facilitates CREB transcriptional properties by inhibiting GSK-3β activity
[15]. I hypothesized that LiCl-treated bOVX mice will express in their hippocampus
higher levels of phosphorylated CREB (pCREB) at serine 133 (CREB’s activation
residue) and higher levels of phosphorylated GSK-3β (pGSK-3β) at serine 9 (GSK-3β’s
inhibitory residue).

I found that in LiCl-treated bOVX mice pGSK-3β increased

compared to non-treated bOVX mice (figure 6B), but this increase was not apparent for
pCREB (figure 6A). No differences were found in levels of pGSK-3β in LiCl-treated
bOVX mice compared with both Sham groups, though (figure 5B).
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Figures 4A-4D. Hippocampal and cortical mRNA expression for ER-α (A), NR1 (B),
Bcl-2 (C), and BDNF (D) using quantitative RT-PCR. *, significant increase compared
to non-treated bOVX; #, significant increase compared to non-treated Sham; †,
significant increase compared to LiCl-treated Sham.
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Figures 5A-5B. Hippocampal protein expression of NR1 (A) and BDNF (B).
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Figures 6A-6B. Hippocampal phosphorylated protein expression of pCREB at serine 133
(A) and pGSK-3β at serine 9 (B).

81

3.4 Discussion
In the laboratory of Dr. Ophelia I. Weeks, my advisor, a former graduate student
performed a study treating male C57BL/6J mice using the same LiCl dosage in the
current study (14.2mM LiCl). Treating male mice with this LiCl dosage increased their
performance in a Morris Water Maze and ORT over a 5 month period (unpublished data).
Atomic absorption spectroscopy analyses of lithium content showed that treating mice
with 14.2mM LiCl in their drinking water maintained a sub-therapeutic level of about
0.2mM lithium (figure 7A). A therapeutic range is 0.6-1.5mM [37]. I later assayed
serum samples from these male LiCl-treated mice for the dominant form of estrogen,
17β-estradiol (E2) and noted that these animals showed elevated E2 plasma-content
(figure 7B). That lithium could increase E2 content in these male mice is consistent with
other studies that showed a lithium-related E2 increase in female rats [1].

In the present study, I specifically wanted to analyze the affect of 14.2mM LiCl
on episodic memory in estrogen-deficient mice since this form of memory is
compromised in women during post-menopause periods [20]. A lack of circulating
estrogen results in uterine atrophy, and I clearly showed that uterine weight of bOVX
mice is significantly lower compared with Sham mice (figure 3B). Interestingly, lithium
is reported to increase cell proliferation and hyperplasia in murine uteri [16].
Furthermore, lithium treatment increases human [6] and murine [51] bone density. But in
the current study, I did not find increases in uterine weight or bone density with lithium
treatment (figure 3A & 3B).

Treatment duration and developmental stage of

experimental animals may account for these differing results since Clément-Lacroix et al.
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[6] used bipolar patients undergoing chronic lithium treatment and Zamani et al. [51]
used up to 12 week old treated mice.
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Figure 7A-7B. Lithium and Estradiol blood content of C57BL/6J male mice. Atomic
absorption spectroscopy depicting lithium-blood content of (mM) (A), and enzyme linked
immunosorbent assay depicting estradiol plasma content (ng/mL) (B).

The ORT performance was not significantly different in LiCl-treated Sham mice
compared with non-treated Sham, but when estrogen is diminished (e.g. bOVX) LiCl
significantly compensated for episodic memory loss compared with non-treated bOVX
mice (figure 2A). Lithium does improve consolidating fear memories mediated by βcatenin and processed by the amygdala [26] and studies show that lithium improves
spatial memory in rats treated with an inhibitor of spatial memory [39]. Additional
studies show that stereotypic behavior induced by apomorphine increased in OVX rats
compared with non-bOVX, but no difference occurred in stereotypic behavior when these
groups were treated with lithium [45]. Similar studies showed that lithium decreased
stereotypic behavior induced by apomorphine in bOVX rats after an abrupt halt of longterm estrogen treatment, but non-estrogen treated bOVX rats did not display this decrease
[7]. In my study, lithium may be compensating molecular mechanism by enhancing
estrogen-mediated signaling in a system with reduced levels of this hormone (e.g.,
bOVX).

Jope [23] proposes a bimodal model for lithium, indicating that lithium

regulates positive and negative cell signaling mechanisms by stabilizing extreme and/or
minimized levels of integral factors involved in these cell signaling mechanisms.
Lithium’s bimodal mechanism may facilitate estrogen-mediated brain cell signaling in an
estrogen-deprived system.

I show that in bOVX mice LiCl significantly increases
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episodic memory and that this coincides with an increase in genes and proteins involved
in learning, memory and neuroprotection (figures 4A-4D and 5A-5B).

In learning or experiencing novel stimuli, recent information is processed in the
hippocampus affecting synaptic connectivity within this brain region. Increased exposure
to this novel stimuli causes synaptic connections to form between hippocampal and
cortical neurons and further exposure causes cortical neurons to form cortico-cortical
neuronal connections [8]. These cortico-cortical neuronal formations are attributed to
long-term memory as opposed to the hippocampus that retains recent information [8]. In
chapter three, I used an ORT to analyze episodic memory and how lithium may affect
this form of memory. Episodic memory is a form of declarative memory, categorized as
long-term memory [41]. Studies do show that mice spend more time with a novel object
than an older one [32]. In this chapter, an increased exposure to a once novel object –
e.g. the priming portion of the ORT (see Experimental procedures) – will be retained in
the mouse’s long-term memory (retention of any stimuli beyond 30 s is considered longterm memory) causing the mouse to investigate the novel object. My results show that in
estrogen deficient mice, LiCl enhances the ability to distinguish the old object versus the
novel one, thereby spending more time investigating the novel object (figure 2A).
According to Hebb’s theory, hippocampal-cortical and cortico-cortical connections
display phase sequences, which are cell assemblies possessing a functional relationship
and responsible for organizing behavior [19].
.
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Synaptic connectivity is facilitated by BDNF and functional NMDA receptors
(heteromeric structures containing the critical subunit NR1) are required for neuronal
communication. An increase in cortico-cortical neuronal connections may explain my
results since I noted higher levels of mRNA expression in the cortex than in the
hippocampus of LiCl-treated bOVX mice (figures 4A-4D), specifically factors involved
in learning and memory.

Lithium does have a temporal range of action since the

literature shows that expression of BDNF and its receptor is dependent on acute rather
than chronic lithium treatment [12].

Protein analysis indicate that LiCl compensated expression of hippocampal NR1
(figure 5A) and BDNF (figure 5B) in a system deprived of estrogen (e.g. bOVX). The
increase in hippocampal NR1 and BDNF expression coincided with higher levels of
inhibited GSK-3β (figure 6B). Attenuation of CREB’s transcriptional properties are
caused by GSK-3β [15]. Although I noted no changes in the activated form of CREB
(figure 6A), I can postulate that in the hippocampus CREB’s transcriptional properties
are not attenuated as much in LiCl-treated bOVX mice compared with non-treated bOVX
mice – this is also noted by the increased cortical genetic expression as well (figures 4A4D and figures 5A-5B). It is worth noting that CREB does facilitates BDNF, Bcl-2 and
NR1 [4, 17, 35]; additionally ER-α mediates CREB activation [27] and ER-α is also
responsible for NMDA receptor subunit transcription [46] – and lithium potentiates
CREB activity [15].
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(Protein analysis of cortical samples would augment this study but complications
arose when isolating cortical protein from TRIzol. There are a number of factors that
fostered these complications including nucleic acid and guanidine contamination which
could have formed aggregates that attenuated protein migration during electrophoresis or
protein degradation. Efforts to remedy these problems are underway).

In addition to my experimental design, I noted that although experimental mice
did not display anxiety, they significantly displayed less anxiety compared to baseline
mice (figure 2B).

This observation provides a better system for obtaining reliable

behavioral data since the experimental mice were handled weekly (see Methods and
Approach) and baseline mice were not – indicating that consistent contact with these
mice reduces anxiety during behavioral testing. Studies do show that mice perform better
on behavioral task in enriched environments [9] and habituating to human contact
provides similar improvements since experimental mice used in my study (with the
exception of non-treated bOVX) performed better in the ORT (figure 2A). Studies do
show that OVX does cause cognitive impairment in mice [11] and may be the reason why
non-treated bOVX mice performed lower than baseline.

The benefits of ERT are debatable since studies have shown that ERT reduces the
development of neurodegenerative diseases and improves cognitive decline [14, 49]; but
these findings have been recently challenged [20].

It seems that the risk of ERT

outweigh its benefits, since ERT also increases breast cancer [31]. Estrogen is essential
for normal brain function by facilitating factors involved in learning, memory and
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neuroprotection. An alternative therapy that mimics the beneficial aspects of estrogen,
without the harmful effects will serve as a better treatment for post-menopausal women.
I describe in this chapter that in mice deprived of estrogen (bOVX), lithium enhances
episodic memory (figure 2A), increases factors involved in learning memory and
neuroprotection (figures 4A-4D and 5A-5B), and increases the inhibitory state of a kinase
(figure 6B) that attenuates learning, memory and neuroprotection.

This evidence

provides great insight into the positive applications of lithium and how it may benefit
post-menopausal women. Though extrapolating results obtained from mice to human
clinical applications is a giant leap, my study serves as a starting point to further
investigate lithium’s potential benefits as an estrogen-mediated signaling modulator in a
system deprived of this hormone.
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CHAPTER IV
Lithium: A Promising Alternative to Estrogen Replacement Therapy
Abstract
Estrogen replacement therapy (ERT) is a topic that engenders much debate since several
studies contradict its efficacy as a palliative therapy for cognitive decline and
neurodegenerative diseases. Signaling transduction pathways can alter brain cell activity,
survival, and morphology by facilitating transcription factor response element binding
and protein production. The steroidal hormone estrogen and the antidepressant drug
lithium can interact through these signaling transduction pathways resulting in
transcription factor activation. The transcription factor cyclic adenosine monophosphate
(cAMP) response element binding protein (CREB) is affected by both estrogen and
lithium. Genes involved in learning, memory and neuronal survival are regulated by
CREB. Activated of CREB is initiated via phosphorylation at serine 133 by protein
kinases and, estrogen and its receptors (ER) facilitate this phosphorylation. Glycogen
synthase kinase-3beta (GSK-3β) attenuates CREB’s transcriptional properties via
subsequent phosphorylation of its serine 129. Lithium is known as a negative regulator
of GSK-3β, thus facilitating CREB response element binding; interestingly, ER-α DNAbinding properties are facilitated by GSK-3β. In this chapter I include protein modeling
depicting estrogen signaling and interactions of CREB/GSK-3β and ER-α/GSK-3β using
I-TASSER and PatchDock web servers. Understanding the molecular pathways of
estrogen will assist identifying a palliative therapy for menopause-related dementia, and
lithium may act as a selective estrogen-mediated signaling modulator.
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4.1 Introduction
Estrogen and lithium exert neuroprotective properties and may act as palliative
treatments for neurodegeneration and cognitive decline [32, 65]. Alzheimer’s disease
(AD) in post-menopausal women is related to estrogen deficiency, and estrogen
replacement therapy (ERT) may benefit post-menopausal women in reducing the risk of
developing AD [30]. Other studies, however, contradict these findings and suggest that
hormone therapy does not improve cognitive decline during menopause, specifically
episodic memory [43]. And, there is a high risk of developing breast cancer, marked by
increased incidences of lobular carcinoma, in post-menopausal women undergoing ERT
[76]. Furthermore, women suffering from depression during peri- and post-menopause
are often prescribed lithium [13, 60]. Few studies focus on how estrogen and lithium
may augment or counteract neuroprotective qualities, and studies demonstrating estrogen
and lithium’s affect on learning and memory are conflicting.

Many underlying

mechanisms still remain to be studied and ever increasing proteonomic- and genomicgenerated data suggest these as complex mechanisms.

Using I-TASSER (Threading/ASSEmbly/Refinement) web server [104, 111, 112]
I fabricated 3-D protein models (figures 1-6), but because of limited parent structures in
the protein data bank (PDB), some models presented in this chapter display low
complexity regions (e.g. indicated primarily by the lighter colored region in the
background of figure 1; subsequent figures are not highlighted as such, though). To
choose the best model for this chapter, predicted models by I-TASSER were compared
by superimposing crystallography structures from the PDB; superimposition was aided

95

by the structure based sequences alignment program (STRAP) and Pymol for visualizing
the superimposition (see table 1 for accession number used to compare each predicted
model). For predicting transmembrane regions I used the TransMembrane prediction
using Hidden Markov Models (TMHMM) web server to locate and specify
transmembrane domains by representing a predicted hydrophobicity chart (specifically
for figure 5A). Literature mining and using the BLAST conserved domain web server
(NCBI) assisted in locating specific amino acids specifying binding residues to produce
the hypothetical protein-protein interactions in this chapter.

Figures depicting these

protein-protein interactions were provided by the PatchDock web server [24, 94].

Table 1.
Predicted Protein

NCBI Accession #

Comparison Protein

PDB Accession #

CREB Isoform B

NP_604391.1

CREB Leucine
Zipper

1dh3

GSK-3β

NP_002084.2

GSK-3β

1q4l

ER-α

NP_000116.2

ER-α

1l2i

GPR30

NP_001091671.1

Rhodopsin

2J4Y

Table 1. Specific amino acid sequences used to fabricate 3-D protein models. These
predicted models were superimposed with crystallography structures from PDB to justify
predicted structures.
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4.2 Neurosteroids and Estrogen Replacement Therapy
Menopause is marked by a massive drop in circulating estrogen. The growing
concern with estrogen deficiency is the increase incidence of neurodegenerative diseases
and cognitive decline. Circulating estrogen permeates the blood-brain barrier [61], and
some speculate α-fetoprotein, a fetal plasma protein with a high affinity for estrogen,
facilitates estrogen neuromechanisms [6, 68]. Estrogen is primarily produced by the
gonads and the adrenal gland, but hormones, known as neurosteroids, are also produced
in the brain [98]. Production of steroids by the gonads requires steroidogenic acute
regulatory protein (StAR) to facilitate intermembrane passage of cholesterol, and StAR is
ubiquitously expressed in the brain, but at low levels [98]. Women with a mutation in the
StAR gene suffer from hormone deficiency leading to spontaneous puberty and an early
onset of menopause [9]. Cholesterol is transported by StAR to the inner mitochondrial
membrane where cytochrome P450 converts cholesterol into pregnenolone, the steroidal
precursor [98]. Astrocytes are a source for steroidogenesis and glia-mediated steroidal
production is linked to neuronal synaptic formation and to facilitating synaptic
transmission [46]. Interestingly, StAR are expressed in glia and this co-localization is
linked to glia-mediated steroidogenesis [98]. Little is known about how ERT affects
StAR or how ERT affects the production of neurosteroids. Should research be directed
towards replacing estrogen in post-menopausal women, or geared towards enhancing
neurosteroidogenisis and estrogen-mediated brain cell signaling pathways?

The benefits of ERT are a controversial topic. As mentioned, women undergoing
ERT increase their risk of breast cancer [76], but there also lies a dichotomy with ERT in
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relation to enhancing cognitive function and reducing neurodegenerative diseases. For
instance, Henderson et al. in 1994 concluded that ERT may reduce the risk of AD and
cognitive decline during post-menopause, but in 2009 Henderson [43] is skeptical of ERT
neuroprotective and neuroenhancing properties. There is also a debate about a critical
window hypothesis. The hypothesis states that if ERT is initiated at a younger age, prior
to menopause, it will improve cognitive functioning [96]; but Henderson considers these
studies systematically bias [43]. Selective estrogen receptor modulators (SERMs) do
provide an alternative to ERT, and studies show a decrease in breast cancer incidence and
slows the progression of osteoporosis [51]. But SERMS use does not seem to improve
cognitive functioning [75, 83]. If SERMs do not influence cognitive functioning an
alternative treatment should be investigated, since estrogen does affect several brain cell
signaling pathways involved in learning, memory and neuroprotection.

4.3 Learning, Memory and Neuroprotection via Estrogen/Estrogen Receptor-mediated
Pathways
Estrogen facilitates brain cell signaling pathways that enhance synaptic plasticity
[62], reduce glutamate excitotoxicity [44], increase neuroprotection of adult hippocampal
cells [63], regulate neurotrophic factors [100], and facilitate transcription factor activation
[67]. Learning and memory are products of gene regulation by transcription factors. For
example, cyclic adenosine monophosphate (cAMP) response element binding protein
(CREB) regulates genes responsible for critical brain functions, including synaptic
plasticity, learning, memory and neuroprotection [44, 53, 88, 102]. Activation of CREB
is facilitated by estrogen [67] leading to the transcription of immediate early genes (e.g.
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c-fos and c-jun), which in turn promotes phenotypical changes – e.g. synaptic plasticity
[92]. In fear conditioning experiments mice exhibit an upregulation of immediate early
genes in the hippocampus and this upregulation is mediated in the amygdala – the
emotion processing center of the brain [47]. Mice with targeted mutations of CREB
exhibit deficiencies in long-term memory storage, but not short-term memory storage
[10]. Activation of CREB’s signaling pathway is initiated by adenylyl cyclase which
catalyzes adenosine triphosphate (ATP) into cAMP that then activates cAMP dependent
protein kinase (PKA) – PKA then phosphorylates CREB at its serine 133 site (figure 1)
[12]. Estrogen and its receptors (ER) facilitate non-genomic molecular pathways by
increasing CREB activity [67] and estrogen is known to increase cAMP levels by binding
to G-protein coupled receptors (GPCR) that stimulate adenylyl cyclase activity [27].

1.
Ser133
Ser129
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Figure 1. Phosphorylating CREB at its serine 133 (green) causes a conformational
change in its leucine zipper region (cyan) causing CREB to dimerize with CREB binding
protein.

This dimerization facilitates CREB response element binding. The

conformational change that occurs, however, exposes CREB’s serine 129 region (red)
allowing a subsequent phosphorylation attenuating CREB’s response element binding.
(The yellow depicts the kinase inducible domain of CREB. The light colored region
indicates the low complexity region)

2.

Figure 2. GSK-3β. The darker magenta areas depict the protein kinase domains of GSK3β.

These regions possess ATP binding, catalytic, activation and substrate binding

domains.
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Glycogen synthase kinase-3beta (GSK-3β; figure 2) is a negative regulator of
CREB via subsequent phosphorylation of CREB at serine 129 (figure 3) and this
subsequent phosphorylation can only occur after the initial phosphorylation of serine 133
[12, 35]. The serine 129 phosphorylation attenuates CREB transcriptional properties thus
inhibiting CREB’s neuroprotective mechanisms [12, 35]. Classically, GSK-3β is well
known for its inhibition of the transcription factor β-catenin in the Wnt signaling pathway
[36]. β-catenin is necessary for activating genes responsible in general for embryonic
development and more specifically for central nervous system development [36]. When
bound by its ligand estrogen, ER-α causes an ephemeral inhibition of GSK-3β via
phosphorylation of its serine residues [14]. ERs also act as ligand-activated transcription
factors for the promoter region estrogen response element (ERE) [30, 64].

To date, there are two known ERs: ERα an d ERβ [97]. In the nervous system,
ERs are mainly located in the hypothalamus and amygdala (two areas responsible for the
gonadal distribution of hormones), but are also located in regions of the cerebral cortex
[70] and hippocampus [30, 97]. Hippocampal expression of ERs are noted in pyramidal
cells and Solum and Handa (2002) measured brain derived neurotrophic factor (BDNF)
mRNA expression in gonadectomized rats and found that BDNF mRNA decreased in the
hippocampus of these gonadectomized rats, but was reversed with a single injection of
estrogen. This group also found that ER-α is co-localized with BDNF in pyramidal cells
of the hippocampus [100], suggesting that ERs may play a role in memory and cognition
[28, 67, 97]. By increasing the activation of second messenger signaling, such as calcium
and cAMP that activate protein kinases [37], which in turn activate CREB, estrogen
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indirectly increases CREB activation [67]. Wu et al. (2005) proposed that estrogen/ER
complex leads to neuroprotection by recruiting phosphatidylinositol-3 kinase (PI3K).
The recruitment of PI3K by ERs increases intracellular calcium; calcium acts as a second
messenger involved in several cell signaling pathways. One specific downstream target
of calcium is protein kinase C (PKC) that activates the Src/extracellular signal-regulated
kinase

(ERK)

signaling

pathway,

leading

to

the

transcription

of

B-cell

lymphoma/leukeimia-2 (Bcl-2), via phosphorylated CREB [105]. PI3K also facilitates
Bcl-2 anti-apoptotic activity by activating Akt which inhibits attenuating factors of Bcl-2
[105]. Promotion of intracellular calcium levels via ER-mediated signaling is debatable
since evidence show a rapid increase in intracellular calcium mediated by estrogen
binding to GPR30, a serpentine transmembrane GPCR [7, 87]. Human keratinocytes
treated with estrogen increases phosphorylated CREB levels and GPR30 anti-sense
oligonucleotides attenuates this increase [52]. The difference in calcium influx mediated
by ERs or GPR30 may be that ER-α has a binding affinity for a Src recruiter known as
proline-, glutamic acid-, and leucine-rich protein-1 (PELP1) [11]. The recruitment of
PELP1 binds Src and may lead to the PI3K/ERK/CREB pathway proposed by Wu et al.
(2005).
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3.

Lys205
Ser129

Figure 3.

Protein-protein interaction of CREB and GSK-3β.

Subsequent

phosphorylation of CREB (cyan) at serine 129 (red) attenuates response element binding,
thereby reducing cAMP-dependent transcription.

Subsequent phosphorylation is

mediated by GSK-3β (magenta) and interaction is noted at lysine 205 (wheat) of GSK3β.
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The dominant form of estrogen, 17β-estradiol (E2), has an affinity for ER-α
(figure 4) leading to transcription factor activation, but E2 can mediate protein signaling
pathways through ERs and non-ERs.

As mentioned, PELP1 is a co-regulator of ER-α

and this interaction leads to Akt/PI3K signaling pathways [11] – a pathway facilitated by
lithium involving GSK-3β inhibition [20]. But E2 also binds to the GPCR, GPR30 a
serpentine receptor. Expression of GPR30 is noted on the plasma membrane but it is also
recognized in the endoplasmic reticulum [89].

The rhodopsin family are GPCRs

possessing the seven transmembrane α-helices and GPR30 share these conserved
domains (figure 5A). Ligand binding of E2 activates GPR30 (figure 5B) and this binding
facilitates cAMP production [89]. Figure 5B depicts ligand binding of E2 to the outer
and inner membrane – these are hypothetical binding sites using PatchDock web server.

Response element binding by ER-α relies on GSK-3β phosphorylation and this
phosphorylation is inhibited in the presence of lithium. Medunjanin et al. [69] suggested
that when GSK-3β is phosphorylated at serine 9 it will disassociate itself from ER-α,
allowing ER-α to migrate to the nucleus for a subsequent phosphorylation by GSK-3β –
consequently activating ER-α transcriptional properties (figure 6). Palindromic DNA
sequences are recognized by ER-α, and expressed in promoter regions for NMDA
receptor subunits [103]; thus, estrogen has a direct genomic role in NMDA receptor
subunit expression.
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4.

Arg394

Figure 4. ER-α. This figure depicts ER-α bound by E2 (blue) at arginine 394 within the
ligand binding domain (foreground; orange). The ligand binding domain also contains
the co-activator recognition site and dimer interface. Domains are conserved in ER-α
classifying it as part of the ER family (background; light orange) and as a transcription
factor due to its zinc finger domain (cyan).
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5A.

5B.

Phe298
Gln54

Arg248
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Figure 5A-5B. GPR30. This superimposition depicts GPR30 (green) sharing similar
structure to rhodopsin (red) (A).

GPR30 express seven α-helices transmembrane

domains (green) and putative binding of E2 (blue) is shown on the outer membrane
(cyan) at phenylalanine 298 and glutamine 54, and inner membrane (cyan) at arginine
248 (B).

6.

Lys205

Ser104

Figure 6. Protein-protein interaction of ER-α and GSK-3β. Once bound by estrogen
(blue), ER-α (orange) mediates cell signaling pathways or acts as a transcription factor.
Response element binding of ER-α is facilitated by GSK-3β (magenta) phosphorylation.
This figure depicts binding of ER-α at serine 104 (green) by lysine 205 (wheat) of GSK-
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3β. The non-bound residues in green (ER-α) and wheat (GSK-3β) are the binding sites
described by Medunjanin et al. [69] and Ilouz et al. [48], respectively. The GSK-3β
amino acid residue responsible for phosphorylating ER-α depicted in this figure is the
same residue that phosphorylates CREB at serine 129 (figure 3).

4.4 Lithium
To elucidate lithium’s prophylactic properties for bipolar disorder, investigators
postulated mechanisms involving inositol depletion [39] and GSK-3β inhibition [33].
Inositol depletion hypothesis states that lithium inhibits inositol monophosphatase thus
depleting the amount of free inositol [39]. Inositol signaling ultimately releases calcium
stored in the endoplasmic reticulum affecting several signaling pathways.

Inositol

signaling via glutamate receptor increases protein kinase activity, transcription factor
activation [78] and is highly involved in synaptic plasticity [26]. Using Dictyostelium
and human neutrophil cell line (HL60), King et al. [55] systematically investigated the
hypothesis that lithium suppresses inositol-mediated signaling. This group showed that
lithium reduces phosphoinositide and this reduction is reversed by over expressing
inositol monophosphatase [55]. Two inositol monophosphatases have been identified
(IMPA1 and IMPA2) and IMPA2 is highly associated not only with bipolar disorder, but
schizophrenia as well [108]. A high concentration of magnesium and a high pH are
required for IMPA2 compared with IMPA1 [81]. Ohnishi et al. (2007) showed that
lithium also inhibits IMPA2 and this inhibition hinders magnesium concentrations.
Bipolar patients treated with lithium show a decrease in inositol monophosphatase
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activity in red blood cells compared with non-treated bipolar patients [58], but
cerebrospinal fluid from lithium-treated patients suffering from bipolar or schizophrenia
show an increase in inositol monophosphatase activity [5].

For over a decade though, studies demonstrate lithium specifically inhibiting
GSK-3β [25, 56] and this inhibition is associated with reducing apoptotic activity [45],
enhancing neurotrophic factors [4], and facilitating CREB DNA binding [35, 82].
Interestingly, learning and memory centers of the brain are influenced by lithium, since
lithium increases performance in hippocampal-dependent spatial memory tasks [95]. An
extensive study using GSK-3β heterozygous knockout mice analyzed behavioral
parameters from apomorphine-induced stereotypic behavior to startle response and found
no distinct difference in behavior [8]. This may lead one to postulate that lithium may
affect learning and memory through GSK-3β independent mechanisms.

Though the mechanism remains elusive, GSK-3β inhibition by lithium is
described as acting through both direct and indirect mechanisms. Indirectly, lithium
inhibits GSK-3β by activating protein kinases that phosphorylate the kinase at its
inhibitory serine 9 residue or by inactivating phosphatases that remove this phosphate
group [50]. Enzymatic activity is highly dependent on magnesium and lithium directly
inhibits GSK-3β by acting as a competitive inhibitor of magnesium; magnesium being a
cofactor for ATP in GSK-3β activation [91].

Thus, GSK-3β inhibition by lithium

protects/rescues the brain from apoptotic cell death; and neural dysfunction results from
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the failure to completely inhibit GSK-3β [35]. In addition, lithium-treated rats show an
upregulation of Bcl-2 in layers II and III of the frontal cortex, dentate gyrus and striatum
[65]. I can reasonable assume that long-term administration of lithium could provide
neuroprotection by increasing neuronal survival. Neuroprotective qualities of lithium are
also associated with increasing BDNF expression and facilitating BDNF signaling via
tyrosine kinase receptor. Rat cortical neurons treated with lithium or BDNF had similar
neuroprotective qualities; however, lithium required a chronic treatment (6 days) as
opposed to an acute action by BDNF (1 day) [42]. These neuroprotective qualities are
attenuated by BDNF neutralizing antibodies and specific inhibitors for tyrosine kinase
[42]. The signaling cascade of BDNF/tyrosine kinase receptor also activates PI3K/Akt
signaling pathways, ultimately leading to neuronal survival and increasing Bcl-2
expression [85]. Neuroprotection of cerebellar granule neurons by lithium via tyrosine
kinase activity is also documented, since this neuroprotection is abolished with tyrosine
kinase inhibitors [34].

Phencyclidine (PCP), also known as angel dust, is an NMDA receptor antagonist
and its actions result in schizophrenic-like behavior [16]; clinically, lithium is also
prescribed for schizophrenia [17]. PCP inhibits PI3K/Akt and ERK signaling pathways,
and PCP activates GSK-3β by facilitating the dephosphorylation of its serine 9 residue,
however, lithium reverses PI3K /Akt and ERK inhibition and GSK-3β activation [106].
Lithium

indirectly

effects

NMDA

receptor

signaling

pathway

phosphorylation and activation of Src-tyrosine kinase activity.

by

reducing

Furthermore,

phosphorylation of NR2 subunits of NMDA receptor by Src tyrosine kinases is essential
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for the receptor’s signal transduction activity and Hashimoto et al. [40] demonstrates that
phosphorylated levels of Src tyrosine kinase decreases in a time-dependent fashion when
treated with lithium.

Although NMDA receptor is highly involved in learning and

memory it also mediates glutamate excitotoxicity, and this mediation reduces
phosphorylated CREB levels [59]. Diminished phosphorylated CREB is regulated by
protein phosphatase 1 [59], a factor involved in GSK-3β activation [110].

When

Kopnisky et al. [59] chronically treated neuronal cultures with lithium, protein
phosphatase 1 activity decreased, thereby increasing phosphorylated CREB levels;
lithium also increased ERK signaling pathway. Post-synaptic glutamate receptors, like
NMDA receptor, facilitates synaptic connectivity and conductivity, and lithium enhances
this facilitation; interestingly, enhanced synaptic plasticity is correlated with
phosphoinositide depletion and not GSK-3β inhibition [54]. Lithium is double-edged in
interacting with glutamate receptors, but only to balance the properties of glutamate
receptor signaling pathways. This means that lithium attenuates glutamate receptormediated excitoxicity [41], but also facilitates, maintains and strengthens glutamate
receptor-mediated synaptic connectivity and communication [54].

If lithium is a

competitive inhibitor of magnesium [91] and glutamate receptor channels bind
magnesium [18], could lithium then directly affect glutamate receptor? Would lithium’s
direct interaction lead to glutamate receptor inhibition or facilitate its activity, or both?
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4.5 Estrogen and Lithium; or, Lithium as a Selective Estrogen-Mediated Signaling
Modulator
To date, few studies focus on the neurobiological affects of combined estrogen
and lithium. Several studies employ lithium in taste aversion task and in inducing
seizures. Seizures are induced by injecting lithium in specific stereotactic brain regions
causing status epilepticus (e.g. seizures) to occur. Estrogen protects rat hippocampus
from these induced seizures; however, this protection is gender specific [29]. Lithium
permeates cells through sodium-potassium ATPase pumps and this permeation is
dependent on sodium-lithium counterflow and exchange [84], which increases
cytoplasmic pH levels thus altering cell activity [57]. Sodium-lithium counterflow is
increased by long-term use of oral contraceptives [2]; interestingly, lithium does not alter
ER-α expression in murine uterine tissue, but ovariectomized mice treated with
combined estrogen and lithium reduces uterine ER-α expression [38].

Taste aversion tasks use lithium to cause an adverse reaction to a rewarding
stimulus (e.g., sucrose water) and studies show that estrogen hinders ovariectomized rats
ability to detect dilute sucrose solutions [19].

Estrogen accelerates extinction of

conditioned taste aversion behavior, but this is dependent on when estrogen was
administered (e.g., before or during extinction) [109]. Combined lithium and estrogen
decreases inflammation of stomach lining, but individual treatment does not affect gastric
erosions [1]. Both estrogen and lithium affect enkephalins, a regulator of nociceptic
responses (e.g., noxious stimuli). In analyzing rat anterior pituitary, Yoshikawa and
Hong (1983), found that enkephalin expression is sex dependent – males express higher

112

levels than females. Administering estrogen to male rats decreases enkephalins, but
testosterone increases enkephalins in the anterior pituitary of female rats [107]. Rats
were also administered lithium and Yoshikawa and Hong [107] noted a decrease in
enkephalins of the anterior pituitary for both male and female rats. This led them to
conclude that the enkephalin system is mediated by the dopamine pathway [107].
Parkinson disease and clinical disorders, such as bipolar disorder, are highly associated
with the dopamine pathway, a pathway affected by both estrogen and lithium [74, 99].

An increase in intracellular sodium concentration mediated by dopaminergic
pathways is a characteristic of bipolar disorder and lithium normalizes this increase [90].
Studies show that combined estrogen and lithium alter serotonin and dopamine
metabolites.

Estrogen does not change serotonin levels, dopamine or dopamine

metabolites in the frontal cortex of ovariectomized rats, but when estrogen is combined
with lithium, dopamine drastically decreases [73]. This decrease is associated with higher
serotonin levels and dopamine metabolites [73]. Apomorphine is a dopaminergic agonist
that increases stereotyped-behavior (e.g., Parkinsonian symptoms) as noted in
ovariectomized rats after discontinuing chronic treatment of estrogen; but this increase in
stereotyped-behavior is diminished with lithium [23].

Lithium does not affect basal levels of cAMP, but when stimulated by dopamine,
lithium inhibits adenylyl cyclase activity and this is shown in vitro and in vivo [72].
Lithium’s inhibition of dopamine-stimulated adenylyl cyclase is not through GPCR
signaling pathway, as indicated using the dopamine receptor agonist, quinpirole [72];

113

interestingly, GTP hydrolysis is decreased by lithium, but not when stimulated by
catecholamines (i.e. dopamine and epinephrine) [79]. There instead seems to be a direct
inhibition of adenylyl cyclase by lithium but only when adenylyl cyclase is activated
[66]. Studies show that lithium hinders hormone and dopamine-stimulated adenylyl
cyclase activity in rat cerebral cortex and this group concluded that lithium is causing this
hindrance via competitive inhibition (e.g. magnesium) [77]. Will lithium inhibit GPR30stimulated adenylyl cyclase activity?

There is a correlation of adenylyl cyclase activity and progression of AD. Postmortem hippocampi of AD patients showed a decrease in adenylyl cyclase activity that
resulted from a hindrance in the catalytic domain [80]. Progression of AD is associated
with producing excessive amounts of the insoluble amyloid beta – a proteolytic product
of amyloid precursor protein (APP) cleaved by β-secretase [31]. Cleavage of APP by αsecretase can produce a soluble product rendering it benign. Estrogen does increase αsecretase mediated cleavage and lithium mimics this increase – potentially through GSK3β inhibition [32]. Post-mortem AD brains also show a decrease in NMDA receptor
subunit mRNA for NR1 and NR2B in the hippocampal formation during advancement of
the disease [71].

Estrogen facilitates calcium influx that promotes factors involved in neuronal
survival and synaptic plasticity [93]. Neurodegenerative diseases, like AD, are marked
by increased excitotoxicity, because of high intracellular calcium levels in brain cells
[22], and postmenopausal women suffer from AD [43]. Should women with a higher
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likelihood of progressive neurodegenerative functions be prescribed ERT? Or should
postmenopausal therapy be directed towards modulating estrogen brain cell signaling
pathways? Lithium is extremely toxic if serum levels exceed therapeutic range (0.6 - 1.4
mM) as shown by treating rats for up to 28 days and lithium increases estrogen levels via
antagonizing ERs [3].

Recent studies, however, indicate that lithium facilitates

proliferation of epithelial cells and these cells show an increased ER expression [86];
lithium also increases estrogen production [15]. Although lithium is classically used to
treat bipolar syndrome it has an incredible propensity for stabilizing molecular
mechanisms. Jope (1999) proposes a bimodal model for lithium, since lithium regulates
positive and negative cell signaling mechanisms resulting in raising basal activities and
reducing maximal activities or by increasing basal levels and reducing maximal levels of
cell signaling mechanisms [49].

Lithium’s bimodal mechanism may facilitate ER-

mediated brain cell signaling during post-menopause by increasing the activity level in a
system deprived of its basal level of estrogen.

4.6 Closing Remarks
Although ERT is used to treat post-menopausal women, studies recognize that
ERT does not alleviate cognitive decline or the advancement of neurodegenerative
diseases.

Therapies should be directed towards enhancing estrogen-mediated

neuromechanisms instead of supplementing the system with estrogen (or hormones in
general). SERMs do provide an alternative to ERT, and, although advancement of
neurodegenerative diseases are attenuated [21], SERMs do not improve cognitive
functioning [75, 83]. Over 60 years ago John Frederick Joseph Cade, an Australian
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psychiatrist, first recognized the calming effects of lithium on small animals and on
himself (Cade, 1949). Since then lithium has been used to treat bipolar disorder and over
a decade has past since the molecular mechanisms for lithium began to be recognized
[56].

These molecular implications have expanded lithium’s profile as a cognitive

enhancer and an anti-neurodegenerative agent [65].

As discussed in this chapter, both estrogen and lithium facilitate a plethora of
signaling transduction pathways resulting in anti-apoptosis, protein expression, learning
and memory. Figure 7 depicts the multitude of pathways affected by estrogen and
suggests ways in which lithium interacts with these signaling transduction pathways. I
noted in chapters one and two, that the combined effects of E2 and LiCl (E2/LiCl)
reduced NMDAR subunit NR1 gene expression and increased glutamate excitotoxicity in
embryonic mouse hippocampal and cortical primary mixed cultures, predominated by
glia [101].

These results were accompanied by noting that combined E2/LiCl also

increased BDNF and ER-α genetic expression (chapter two). I also showed that lithium
treatment alone can increase episodic memory and that this coincides with enhanced
expression of markers involved in learning, memory and neuroprotection (chapter three).
The research presented in this dissertation is still in its infancy and care must be taken in
considering these results applicability towards any clinical implications; but I believe to
further study the involvement of antidepressants and hormones will provide a better
treatment regime for post-menopausal women.
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Figure 7. A post-synaptic cell signaling schematic of the mechanism described in this
chapter. ATP, adenosine triphosphate; CREB, cyclic adenosine monophosphate (cAMP)
response element binding protein; ER, estrogen receptor; GPR30, G–protein coupled
receptor 30; GSK-3β, glycogen synthase-3beta; NMDAR, N-methyl-D-aspartate; PKA,
cAMP dependent protein kinase. (

, putative interaction;

, inhibitory)

117

, activating/interacting;

REFERENCES
[1]

M. Abouzeit-Har, T. Verimer, J. Long, Effect of long term estrogen and lithium
treatment on restraint induced gastric erosion in intact and ovariectomized rats,
Die Pharmazie 37 (1982) 593-595.

[2]

G. Adebayo, L. Norris, M. Devitt, J. Bonnar, J. Feely, Effects of oral
contraceptives containing different progestogens on sodium-lithium
countertransport in normal females., Journal of Human Hypertension 12 (1998)
235-238.

[3]

M. Allagui, N. Hfaiedh, C. Vincent, F. Guermazi, J. Murat, F. Croute, A. El Feki,
Changes in growth rate and thyroid- and sex-hormones blood levels in rats under
sub-chronic lithium treatment., Hum. Exp. Toxicol. 25 (2006) 243-250.

[4]

F. Angelucci, L. Aloe, P. Jiménez-Vasquez, A.A. Mathé, Lithium treatment alters
brain concentrations of nerve growth factor, brain-derived neurotrophic factor and
glial cell line-derived neurotrophic factor in a rat model of depression, Int. J.
Neuropsychopharmacol. 6 (2003) 225-231.

[5]

J.R. Atack, J. Levine, R.H. Belmaker, Cerebrospinal fluid inositol
monophosphatase: elevated activity in depression and neuroleptic-treated
schizophrenia, Biol. Psychiatry 44 (1998) 433-437.

[6]

J. Bakker, M.J. Baum, Role for estradiol in female-typical brain and behavioral
sexual differentiation, Front. Neuroendocrinol. 29 (2008) 1-16.

[7]

S.M. Belcher, Rapid signaling mechanisms of estrogens in the developing
cerebellum, Brain Res. Rev. 57 (2008) 481-492.

[8]

Y. Bersudsky, A. Shaldubina, N. Kozlovsky, J.R. Woodgett, G. Agam, R.H.
Belmaker, Glycogen synthase kinase-3β heterozygote knockout mice as a model
of findings in postmortem schizophrenia brain or as a model of behaviors
mimicking lithium action: negative results, Behav. Pharmacol. 19 (2008) 217-224
210.1097/FBP.1090b1013e3282feb1099.

[9]

A. Bhangoo, E. Buyuk, K. Oktay, S. Ten, Phenotypic features of 46, XX females
with StAR protein mutations., Pediatr. Endocrinol. Rev. 5 ( 2007 ) 633-641.

[10]

R. Bourtchuladze, B. Frenguelli, J. Blendy, D. Cioffi, G. Schutz, A.J. Silva,
Deficient long-term memory in mice with a targeted mutation of the cAMPresponsive element-binding protein, Cell 79 (1994) 59-68.

[11]

D.W. Brann, Q.-G. Zhang, R.-M. Wang, V.B. Mahesh, R.K. Vadlamudi, PELP1 –
A novel estrogen receptor-interacting protein, Mol. Cell. Endocrinol. 290 (2008)
2-7.

118

[12]

B.P. Bullock, J.F. Habener, Phosphorylation of the cAMP Response Element
Binding Protein CREB by cAMP-Dependent Protein Kinase A and Glycogen
Synthase Kinase-3 Alters DNA-Binding Affinity, Conformation, and Increases
Net Charge, Biochemistry 37 (1998) 3795-3809.

[13]

V.K. Burt, N. Rasgon, Special considerations in treating bipolar disorder in
women, Bipolar Disord. 6 (2004) 2-13.

[14]

P. Cardona-Gomez, M. Perez, J. Avila, L.M. Garcia-Segura, F. Wandosell,
Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3,
and beta-catenin in the hippocampus, Mol. Cell. Neurosci. 25 (2004) 363-373.

[15]

S.-Y. Choe, S.-J. Kim, H.-G. Kim, J.H. Lee, Y. Choi, H. Lee, Y. Kim, Evaluation
of estrogenicity of major heavy metals, The Science of The Total Environment
312 (2003) 15-21.

[16]

Y. Choi, S. Snigdha, M. Shahid, J. Neill, F. Tarazi, Subchronic Effects of
Phencyclidine on Dopamine and Serotonin Receptors: Implications for
Schizophrenia, J. Mol. Neurosci. 38 (2009) 227-235.

[17]

L. Citrome, Adjunctive lithium and anticonvulsants for the treatment of
schizophrenia: what is the evidence?, Expert Reviews 9 (2009) 55-71.

[18]

R.J. Clarke, J.W. Johnson, Voltage-dependent gating of NR1/2B NMDA
receptors, J. Physiol. (Lond.) 586 (2008) 5727-5741.

[19]

K.S. Curtis, J.M. Stratford, R.J. Contreras, Estrogen increases the taste threshold
for sucrose in rats, Physiol. Behav. 86 (2005) 281-286.

[20]

P. De Sarno, X. Li, R.S. Jope, Regulation of Akt and glycogen synthase kinase3[beta] phosphorylation by sodium valproate and lithium, Neuropharmacology 43
(2002) 1158.

[21]

K.M. Dhandapani, D.W. Brann, Protective Effects of Estrogen and Selective
Estrogen Receptor Modulators in the Brain, Biol. Reprod. 67 (2002) 1379-1385.

[22]

X.-x. Dong, Y. Wang, Z.-h. Qin, Molecular mechanisms of excitotoxicity and
their relevance to pathogenesis of neurodegenerative diseases, Acta Pharmacol.
Sin. 30 (2009) 379-387.

[23]

V.A.C. Dorce, J. Palermo-Neto, Lithium effects on estrogen-induced
dopaminergic supersensitivity in rats, Brain Res. Bull. 29 (1992) 239-241.

[24]

D. Duhovny, R. Nussinov, H. Wolfson, Efficient Unbound Docking of Rigid
Molecules. In: E. Gusfield et al. (Ed.), Lecture Notes in Computer Science, Vol.
2452, Springer Verlag, Rome, Italy, 2002, pp. 185-200.

119

[25]

T. Engel, P. Goñi-Oliver, E. Gómez de Barreda, J.J. Lucas, F. Hernández, J.
Avila, Lithium, a Potential Protective Drug in Alzheimer's Disease,
Neurodegenerative Diseases 5 (2008) 247-249.

[26]

D. Fernandez de Sevilla, A. Nunez, M. Borde, R. Malinow, W. Buno,
Cholinergic-Mediated IP3-Receptor Activation Induces Long-Lasting Synaptic
Enhancement in CA1 Pyramidal Neurons, J. Neurosci. 28 (2008) 1469-1478.

[27]

E.J. Filardo, J.A. Quinn, A.R. Frackelton, Jr., K.I. Bland, Estrogen Action Via the
G Protein-Coupled Receptor, GPR30: Stimulation of Adenylyl Cyclase and
cAMP-Mediated Attenuation of the Epidermal Growth Factor Receptor-to-MAPK
Signaling Axis, Mol. Endocrinol. 16 (2002) 70-84.

[28]

H.N. Fugger, T.C. Foster, J.-A. Gustafsson, E.F. Rissman, Novel effects of
estradiol and estrogen receptor α and β on cognitive function, Brain Res. 883
(2000) 258-264.

[29]

A.S. Galanopoulou, E.M. Alm, J. Veliskova, Estradiol reduces seizure-induced
hippocampal injury in ovariectomized female but not in male rats, Neurosci. Lett.
342 (2003) 201.

[30]

L.M. Garcia-Segura, I. Azcoitia, L.L. DonCarlos, Neuroprotection by estradiol,
Prog. Neurobiol. 63 (2001) 29-60.

[31]

G. Glenner, Alzheimer's disease (senile dementia) a research update and critique
with recommendations., Journal of Geriatric Society 30 (1982) 59-62.

[32]

S. Goodenough, M. Schafer, C. Behl, Estrogen-induced cell signalling in a
cellular model of Alzheimer's disease, J. Steroid Biochem. Mol. Biol. 84 (2003)
301-305.

[33]

T.D. Gould, H.K. Manji, The Wnt Signaling Pathway in Bipolar Disorder,
Neuroscientist 8 (2002) 497-511.

[34]

S. Grignon, N. Levy, F. Couraud, B. Bruguerolle, Tyrosine kinase inhibitors and
cycloheximide inhibit Li+ protection of cerebellar granule neurons switched to
non-depolarizing medium, Eur. J. Pharmacol. 315 (1996) 111-114.

[35]

C.A. Grimes, R.S. Jope, CREB DNA binding activity is inhibited by glycogen
synthase kinase-3β and facilitated by lithium, J. Neurochem. 78 (2001) 12191232.

[36]

C.A. Grimes, R.S. Jope, The multifaceted roles of glycogen synthase kinase 3β in
cellular signaling, Prog. Neurobiol. 65 (2001) 391-426.

120

[37]

G. Gu, A.A. Rojo, M.C. Zee, J. Yu, R.B. Simerly, Hormonal Regulation of CREB
Phosphorylation in the Anteroventral Periventricular Nucleus, J. Neurosci. 16
(1996) 3035-3044.

[38]

A.G. Gunin, V.U. Emelianov, I.U. Mironkin, M.P. Morozov, A.S. Tolmachev,
Lithium treatment enhances estradiol-induced proliferation and hyperplasia
formation in the uterus of mice, European Journal of Obstetrics, Gynecology and
Reproductive Biology 114 (2004) 83-91.

[39]

A.J. Harwood, Lithium and bipolar mood disorder: the inositol-depletion
hypothesis revisited, Mol. Psychiatry 10 (2004) 117-126.

[40]

R. Hashimoto, K. Fujimaki, M.R. Jeong, L. Christ, D.-M. Chuang, Lithiuminduced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in
neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity,
FEBS Lett. 538 (2003) 145-148.

[41]

R. Hashimoto, C. Hough, T. Nakazawa, T. Yamamoto, D.-M. Chuang, Lithium
protection against glutamate excitotoxicity in rat cerebral cortical neurons:
involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine
phosphorylation, J. Neurochem. 80 (2002) 589-597.

[42]

R. Hashimoto, N. Takei, K. Shimazu, L. Christ, B. Lu, D.-M. Chuang, Lithium
induces brain-derived neurotrophic factor and activates TrkB in rodent cortical
neurons: An essential step for neuroprotection against glutamate excitotoxicity,
Neuropharmacology 43 (2002) 1173.

[43]

V.W. Henderson, Menopause, cognitive ageing and dementia: practice
implications, Menopause International 15 (2009) 41-44.

[44]

K. Honda, S. Shimohama, H. Sawada, T. Kihara, T. Nakamizo, H. Shibasaki, A.
Akaike, Nongenomic antiapoptotic signal transduction by estrogen in cultured
cortical neurons, J. Neurosci. Res. 64 (2001) 466-475.

[45]

V. Hongisto, N. Smeds, S. Brecht, T. Herdegen, M.J. Courtney, E.T. Coffey,
Lithium Blocks the c-Jun Stress Response and Protects Neurons via Its Action on
Glycogen Synthase Kinase 3, Mol. Cell. Biol. 23 (2003) 6027-6036.

[46]

R. Hu, W.Q. Cai, X.G. Wu, Z. Yang, Astrocyte-derived estrogen enhances
synapse formation and synaptic transmission between cultured neonatal rat
cortical neurons, Neuroscience 144 (2007) 1229-1240.

[47]

N.C. Huff, M. Frank, K. Wright-Hardesty, D. Sprunger, P. Matus-Amat, E.
Higgins, J.W. Rudy, Amygdala Regulation of Immediate-Early Gene Expression
in the Hippocampus Induced by Contextual Fear Conditioning, Journal of
Neuroscience, 26 (2006) 1616-1623.

121

[48]

R. Ilouz, N. Kowalsman, M. Eisenstein, H. Eldar-Finkelman, Identification of
Novel Glycogen Synthase Kinase-3beta Substrate-interacting Residues Suggests a
Common Mechanism for Substrate Recognition. Vol. 281, 2006, pp. 3062130630.

[49]

R.S. Jope, A bimodal model of the mechanism of action of lithium, Mol.
Psychiatry 4 (1999) 21-25.

[50]

R.S. Jope, Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple
outcomes, Trends Pharmacol. Sci. 24 (2003) 441-443.

[51]

V.C. Jordan, S. Gapstur, M. Morrow, Selective Estrogen Receptor Modulation
and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart
Disease, J. Natl. Cancer Inst. 93 (2001) 1449-1457.

[52]

N. Kanda, S. Watanabe, 17β-Estradiol Stimulates the Growth of Human
Keratinocytes by Inducing Cyclin D2 Expression, J. Investig. Dermatol. 123
(2004) 319-328.

[53]

E.R. Kandel, The Molecular Biology of Memory Storage: A Dialogue Between
Genes and Synapses, Science 294 (2001) 1030-1038.

[54]

H.J. Kim, S.A. Thayer, Lithium Increases Synapse Formation between
Hippocampal Neurons by Depleting Phosphoinositides, Mol. Pharmacol. 75
(2009) 1021-1030.

[55]

J.S. King, R. Teo, J. Ryves, J.V. Reddy, O. Peters, B. Orabi, O. Hoeller, R.S.B.
Williams, A.J. Harwood, The mood stabiliser lithium suppresses PIP3 signalling
in Dictyostelium and human cells, Disease Models and Mechanisms 2 (2009)
306-312.

[56]

P.S. Klein, D.A. Melton, A molecular mechanism for the effect of lithium
on development, PNAS 93 (1996) 8455-8459.

[57]

Y. Kobayashi, T. Pang, T. Iwamoto, S. Wakabayashi, M. Shigekawa, Lithium
activates mammalian Na+/H+ exchangers: isoform specificity and inhibition by
genistein, Pflügers Archiv European Journal of Physiology 439 (2000) 455-462.

[58]

O. Kofman, R. Belmaker, Biochemical, behavioral, and clinical studies of the role
of inositol in lithium treatment and depression, Biol. Psychiatry 34 (1993) 839852.

[59]

K.L. Kopnisky, E. Chalecka-Franaszek, M. Gonzalez-Zulueta, D.M. Chuang,
Chronic lithium treatment antagonizes glutamate-induced decrease of
phosphorylated CREB in neurons via reducing protein phosphatase 1 and
increasing MEK activities, Neuroscience 116 (2003) 425.

122

[60]

A. Kukopulos, G. Minnai, B. Muller-Oerlinghausen, The influence of mania and
depression on the pharmacokinetics of lithium: A longitudinal single-case study,
J. Affect. Disord. 8 (1985) 159-166.

[61]

S.J. Lee, B.S. McEwen, Neurophic and Neuroprotective Actions of Estrogens and
their Therapeutic Implications, Annu. Rev. Pharmacol. Toxicol. 41 (2001) 569591.

[62]

C. Leranth, M. Shanabrough, D.E. Redmond Jr., Gonadal hormones are
responsible for maintaining the integrity of spine synapses in the CA1
hippocampal subfield of female nonhuman primates, The Journal of Comparative
Neurology 447 (2002) 34-42.

[63]

Z. Liu, Myriam Gastard, Tatyana Verina, Susan Bora, Peter R. Mouton, Vassilis
E. Koliatsos Estrogens modulate experimentally induced apoptosis of granule
cells in the adult hippocampus, J. Comp. Neurol. 441 (2001) 1-8.

[64]

J.I. Macgregor, V.C. Jordan, Basic Guide to the Mechanisms of Antiestrogen
Action, Pharmacol. Rev. 50 (1998) 151-196.

[65]

H.K. Manji, G.J. Moore, G. Chen, Lithium at 50: have the neuroprotective effects
of this unique cation been overlooked?, Biol. Psychiatry 46 (1999) 929-940.

[66]

L. Mann, E. Heldman, G. Shaltiel, R.H. Belmaker, G. Agam, Lithium
preferentially inhibits adenylyl cyclase V and VII isoforms, Int. J.
Neuropsychopharmacol. 11 (2008) 533-539.

[67]

B.S. McEwen, Genome and Hormones: Gender Differences in Physiology:
Invited Review: Estrogens effects on the brain: multiple sites and molecular
mechanisms, J. Appl. Physiol. 91 (2001) 2785-2801.

[68]

B.S. McEwen, L. Plapinger, C. Chaptal, J. Gerlach, G. Wallach, Role of
fetoneonatal estrogen binding proteins in the associations of estrogen with
neonatal brain cell nuclear receptors, Brain Res. 96 (1975) 400-406.

[69]

S. Medunjanin, A. Hermani, B. De Servi, J. Grisouard, G. Rincke, D. Mayer,
Glycogen Synthase Kinase-3 Interacts with and Phosphorylates Estrogen
Receptor α and Is Involved in the Regulation of Receptor Activity, J. Biol. Chem.
280 (2005) 33006-33014.

[70]

I. Merchenthaler, M.V. Lane, S. Numan, T.L. Dellovade, Distribution of estrogen
receptor α and β in the mouse central nervous system: In vivo autoradiographic
and immunocytochemical analyses, J. Comp. Neurol. 473 (2004) 270-291.

[71]

A.J. Mishizen-Eberz, R.A. Rissman, T.L. Carter, M.D. Ikonomovic, B.B. Wolfe,
D.M. Armstrong, Biochemical and molecular studies of NMDA receptor subunits

123

NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's
disease pathology, Neurobiol. Dis. 15 (2004) 80-92.
[72]

L.P. Montezinho, A. Mørk, C.B. Duarte, S. Penschuck, C.F.G.C. Geraldes,
M.M.C.A. Castro, Effects of mood stabilizers on the inhibition of adenylate
cyclase via dopamine D(2)-like receptors, Bipolar Disord. 9 (2007) 290-297.

[73]

M. Morissette, T. Di Paolo, Acute effect of 17β-estradiol and lithium on
ovariectomized rat brain biogenic amines metabolism, J. Psychiatr. Res. 30 (1996)
95-107.

[74]

M. Morissette, M. Le Saux, M. D'Astous, S. Jourdain, S. Al Sweidi, N. Morin, E.
Estrada-Camarena, P. Mendez, L.M. Garcia-Segura, T. Di Paolo, Contribution of
estrogen receptors alpha and beta to the effects of estradiol in the brain, J. Steroid
Biochem. Mol. Biol. 108 (2008) 327-338.

[75]

V. Natale, P. Albertazzi, N. Missiroli, D. Pedrini, M. Salgarello, Effects of
raloxifene on mood, sleep, libido and cognitive function in postmenopausal
healthy women: a pilot study, Maturitas 48 (2004) 59-63.

[76]

L.M. Newcomer, P.A. Newcomb, J.D. Potter, Y. Yasui, A. Trentham-Dietz, B.E.
Storer, M.P. Longnecker, J.A. Baron, J.R. Daling, Postmenopausal hormone
therapy and risk of breast cancer by histologic type United States, Cancer Causes
& Control 14 (2003) 225-233.

[77]

M.E. Newman, R.H. Belmaker, Effects of lithium in vitro and ex vivo on
components of the adenylate cyclase system in membranes from the cerebral
cortex of the rat, Neuropharmacology 26 (1987) 211-217.

[78]

K.J. O'Riordan, I.C. Huang, M. Pizzi, P. Spano, F. Boroni, R. Egli, P. Desai, O.
Fitch, L. Malone, H. Jin Ahn, H.-C. Liou, J.D. Sweatt, J.M. Levenson, Regulation
of Nuclear Factor {kappa}B in the Hippocampus by Group I Metabotropic
Glutamate Receptors, J. Neurosci. 26 (2006) 4870-4879.

[79]

Y. Odagaki, N. Nishi, T. Koyama, Lack of Interfering Effects of Lithium on
Receptor/G Protein Coupling in Human Platelet and Rat Brain Membranes, Biol.
Psychiatry 42 (1997) 697-703.

[80]

T. Ohm, J. Bohl, B. Lemmer, Reduced basal and stimulated (isoprenaline,
Gpp(NH)p, forskolin) adenylate cyclase activity in Alzheimer's disease correlated
with histopathological changes., Brain Res. 540 (1991) 229-236.

[81]

T. Ohnishi, H. Ohba, K.-C. Seo, J. Im, Y. Sato, Y. Iwayama, T. Furuichi, S.-K.
Chung, T. Yoshikawa, Spatial Expression Patterns and Biochemical Properties
Distinguish a Second myo-Inositol Monophosphatase IMPA2 from IMPA1, J.
Biol. Chem. 282 (2007) 637-646.

124

[82]

N. Ozaki, D.-M. Chuang, Lithium Increases Transcription Factor Binding to AP-1
and Cyclic AMP-Responsive Element in Cultured Neurons and Rat Brain, J.
Neurochem. 69 (1997) 2336-2344.

[83]

J. Palmer, T. Trotter, A. Joy, L. Carlson, Cognitive effects of Tamoxifen in premenopausal women with breast cancer compared to healthy controls, Journal of
Cancer Survivorship 2 (2008) 275-282.

[84]

G.N. Pandey, B. Sarkadi, M. Haas, R.B. Gunn, J.M. Davis, D.C. Tosteson,
Lithium transport pathways in human red blood cells, J. Gen. Physiol. 72 (1978)
233-247.

[85]

A. Patapoutian, L.F. Reichardt, Trk receptors: mediators of neurotrophin action,
Curr. Opin. Neurobiol. 11 (2001) 272-280.

[86]

A.J. Polotsky, L. Zhu, N. Santoro, J.W. Pollard, Lithium chloride treatment
induces epithelial cell proliferation in xenografted human endometrium, Hum.
Reprod. (2009) dep115.

[87]

E.R. Prossnitz, M. Maggiolini, Mechanisms of estrogen signaling and gene
expression via GPR30, Mol. Cell. Endocrinol. In Press, Corrected Proof (2009).

[88]

S. Pugazhenthi, A. Nesterova, C. Sable, K.A. Heidenreich, L.M. Boxer, L.E.
Heasley, J.E.B. Reusch, Akt/Protein Kinase B Up-regulates Bcl-2 Expression
through cAMP-response Element-binding Protein, J. Biol. Chem. 275 (2000)
10761-10766.

[89]

L. Raz, M.M. Khan, V.B. Mahesh, R.K. Vadlamudi, D.W. Brann, Rapid Estrogen
Signaling in the Brain, NeuroSignals 16 (2008) 140-153.

[90]

R.J. Roberts, R. Repass, R.S. El-Mallakh, Effect of dopamine on intracellular
sodium: A common pathway for pharmacological mechanism of action in bipolar
illness, World Journal of Biological Psychiatry 24 (2009) 1-7.

[91]

W.J. Ryves, A.J. Harwood, Lithium Inhibits Glycogen Synthase Kinase-3 by
Competition for Magnesium, Biochem. Biophys. Res. Commun. 280 (2001) 720725.

[92]

S. Sanyal, D.J. Sandstrom, C.A. Hoeffer, M. Ramaswami, AP-1 functions
upstream of CREB to control synaptic plasticity in Drosophila, Nature 416 (2002)
870.

[93]

S.N. Sarkar, R.-Q. Huang, S.M. Logan, K.D. Yi, G.H. Dillon, J.W. Simpkins,
Estrogens directly potentiate neuronal L-type Ca2+ channels, Proceedings of the
National Academy of Sciences 105 (2008) 15148-15153.

125

[94]

D. Schneidman-Duhovny, Y. Inbar, R. Nussinov, H. Wolfson, PatchDock and
SymmDock: servers for rigid and symmetric docking., Nucleic Acids Res. 33
(2005) W363-367.

[95]

M. Sharifzadeh, M. Aghsami, S. Gholizadeh, K. Tabrizian, M. Soodi, S. Khalaj,
A. Ranjbar, A. Hosseini-Sharifabad, A. Roghani, M.H. Karimfar, Protective
Effects of Chronic Lithium Treatment against Spatial Memory Retention Deficits
Induced by the Protein Kinase AII Inhibitor H-89 in Rats, Pharmacology 80
(2007) 158-165.

[96]

B.B. Sherwin, Estrogen and Cognitive Functioning in Women, Endocr. Rev. 24
(2003) 133-151.

[97]

P.J. Shughrue, M.V. Lane, I. Merchenthaler, Comparative distribution of estrogen
receptor-α and -β mRNA in the rat central nervous system, J. Comp. Neurol. 388
(1997) 507-525.

[98]

A. Sierra, Neurosteroids: The StAR Protein in the Brain, J. Neuroendocrinol. 16
(2004) 787-793.

[99]

T. Silverstone, Dopamine in manic depressive illness : A pharmacological
synthesis, J. Affect. Disord. 8 (1985) 225-231.

[100] D.T. Solum, R.J. Handa, Estrogen Regulates the Development of Brain-Derived
Neurotrophic Factor mRNA and Protein in the Rat Hippocampus, J. Neurosci. 22
(2002) 2650-2659.
[101] J.J. Valdés, O.I. Weeks, Estradiol and lithium chloride specifically alter NMDA
receptor subunit NR1 mRNA and excitotoxicity in primary cultures, Brain Res.
1268 (2009) 1-12.
[102] M.R. Walton, M. Dragunow, Is CREB a key to neuronal survival?, Trends
Neurosci. 23 (2000) 48-53.
[103] T. Watanabe, S. Inoue, H. Hiroi, A. Orimo, M. Muramatsu, NMDA receptor type
2D gene as target for estrogen receptor in the brain, Mol. Brain Res. 63 (1999)
375-379.
[104] S. Wu, J. Skolnick, Y. Zhang., Ab initio modeling of small proteins by iterative
TASSER simulations, BMC Biology 5 (2007) 17
[105] T.W. Wu, J.M. Wang, S. Chen, R.D. Brinton, 17β-estradiol induced Ca2+ influx
via L-type calcium channels activates the Src/ERK/cyclic-AMP response element
binding protein signal pathway and BCL-2 expression in rat hippocampal
neurons: A potential initiation mechanism for estrogen-induced neuroprotection,
Neuroscience 135 (2005) 59-72.

126

[106] Y. Xia, C.Z. Wang, J. Liu, N.C. Anastasio, K.M. Johnson, Lithium Protection of
Phencyclidine-Induced Neurotoxicity in Developing Brain: The Role of
Phosphatidylinositol-3 Kinase/Akt and Mitogen-Activated Protein Kinase
Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways, J. Pharmacol.
Exp. Ther. 326 (2008) 838-848.
[107] K. Yoshikawa, J. Hong, The enkephalin system in the rat anterior pituitary:
regulation by gonadal steroid hormones and psychotropic drugs, Endocrinology
113 (1983) 1218-1227.
[108] T. Yoshikawa, M. Kikuchi, K. Saito, A. Watanabe, K. Yamada, H. Shibuya, M.
Nankai, A. Kurumaji, E. Hattori, H. Ishiguro, H. Shimizu, Y. Okubo, M. Toru, S.
Detera-Wadleigh, Evidence for association of the myo-inositol monophosphatase
2 (IMPA2) gene with schizophrenia in Japanese samples, Mol. Psychiatry 6 (2001
) 202-210.
[109] D.L. Yuan, K.C. Chambers, Estradiol Accelerates Extinction of Lithium
Chloride-Induced Conditioned Taste Aversions Through Its Illness-Associated
Properties, Horm. Behav. 36 (1999) 287.
[110] F. Zhang, C.J. Phiel, L. Spece, N. Gurvich, P.S. Klein, Inhibitory Phosphorylation
of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium: Evidence for
Autoregulation of GSK-3, J. Biol. Chem. 278 (2003) 33067-33077.
[111] Y. Zhang, I-TASSER server for protein 3D structure prediction., BMC
Bioinformatics 9 (2008) 40
[112] Y. Zhang, Template-based modeling and free modeling by I-TASSER in CASP7,
Proteins Struct. Funct. Bioinformat. 8 (2007) 108-117.

127

VITA
JAMES JASON VALDÉS
1996-1998

A.A., Psychology
Miami-Dade Community College
Miami, FL

1998-2001

B.A., Psychology
Florida International University
Miami, FL

2004 - 2005

Teaching Assistant
Florida International University, Department
of Biological Sciences
Miami, FL

2003-2009

Laboratory Manager and Research Assistant
Florida International University, Department
of Biological Sciences,
Miami, FL

SELECTED PEER-REVIEWED PUBLICATIONS, PRESENTATION AND POSTERS
Valdés, J.J. and Weeks, O.I. (2009). Estradiol and Lithium Chloride Specifically Alter
NMDA Receptor Subunit NR1 mRNA and Excitotoxicity in Primary Cultures.
Neuroscience Letters. (Under Review).
Valdés, J.J. and Weeks, O.I. (2009). Estradiol and Lithium Chloride Specifically Alter
NMDA Receptor Subunit NR1 mRNA and Excitotoxicity in Primary Cultures. Brain
Research. 1268:1-12.
Valdés, J.J. and Weeks, O.I. (2004). Lithium and Estrogen: A Synergistic Relationship?
A presentation at the Minority Biomedical Research Support Annual symposium, Florida
International University, Miami, FL.
Valdés, J.J. and Weeks, O.I. (2004).Lithium: A Memory Enhancer? A presentation at the
Comparative Immunology 5thAnnual Symposium (Florida International University,
Miami, FL)

128

Valdés, J.J. and Weeks, O.I. (2007). From Behavior to Molecules: Preliminary
Observation on Lithium’s effect on Learning, Memory and Neuroprotection. A
presentation at the Department of Biological Sciences Annual Symposium, Florida
International University, Miami, FL.
Valdés, J.J. and Weeks, O.I. (2007). An Odyssey to Better Understand Morphological
and Molecular Processes Involved in Learning and Memory. A presentation at the
Comparative Immunology 8th Annual Symposium, Florida International University,
Miami, FL.
Valdés, J.J. and Weeks, O.I. (2007). Observations of Lithium’s and Estrogen’s Effect on
Gene Expression Involved in Learning, Memory and Neuroprotection. A presentation at
the Minority Biomedical Research Support Annual symposium, Florida International
University, Miami, FL.
Valdés, J.J. and Weeks, O.I. (2008). Exposure of cultured murine brain cells to both
lithium and estrogen results in altered NR1 and GSK-3 beta mRNA expression. Platform
presentation at the American Association of Anatomists (Federation of American
Societies for Experimental Biology (FASEB)) annual meeting, San Diego, CA.
Valdés, J.J. and Weeks, O.I. (2008). Estrogen and Lithium Alter NMDAR subunit NR1
mRNA and Cell Viability in Cortical and Hippocampal Brain Cell Cultures. A
presentation at the Minority Biomedical Research Support Annual symposium, Florida
International University, Miami, FL.
Valdés, J.J. and Weeks, O.I. (2005). Lithium: A Memory Enhancer. Poster Presentation
at the American Association of Anatomists (Federation of American Societies for
Experimental Biology (FASEB)) annual meeting, San Diego, CA.
Valdés, J.J. and Weeks, O.I. (2006). Lithium Chloride Upregulates Bcl-2 Protein
Expression in the Frontal Cortex, Hippocampus and Amygdala of C57BL/6J mice.
Poster Presentation at the 36th Annual Society for Neuroscience meeting, Atlanta, GA.
Valdés, J.J. and Weeks, O.I. (2009). Viability of estrogen and lithium-treated primary
brain cell cultures following glutamate insult and NR1 mRNA expression of pretreated
cultures. Poster Presentation at the American Association of Anatomists (Federation of
American Societies for Experimental Biology (FASEB)) annual meeting, New Orleans,
LA.

129

